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Abstract
The RATPAC (Randomised Assessment of Treatment 
using Panel Assay of Cardiac markers) trial: a 
randomised controlled trial of point-of-care cardiac 
markers in the emergency department
S Goodacre,1* M Bradburn,1 P Fitzgerald,1 E Cross,1 P Collinson,2 
A Gray3 and AS Hall4
1School of Health and Related Research, University of Sheffield, Sheffield, UK
2St George’s Hospital, London, UK
3Royal Infirmary of Edinburgh, Lothian Health Board, Edinburgh, UK
4Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK
*Corresponding author  s.goodacre@sheffield.ac.uk
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of using a point-
of-care cardiac marker panel in patients presenting to the emergency department (ED) with 
suspected but not proven acute myocardial infarction (AMI).
Design: Multicentre pragmatic open randomised controlled trial and economic evaluation.
Setting: Six acute hospital EDs in the UK.
Participants: Adults presenting to hospital with chest pain due to suspected but not 
proven myocardial infarction, and no other potentially serious alternative pathology 
or comorbidity.
Interventions: Participants were allocated using an online randomisation system to receive 
either (1) diagnostic assessment using the point-of-care biochemical marker panel or 
(2) conventional diagnostic assessment without the panel. All tests and treatments other 
than the panel were provided at the discretion of the clinician.
Main outcome measures: The primary outcome was the proportion of patients 
successfully discharged home after ED assessment, defined as patients who had 
(1) either left the hospital or were awaiting transport home with a discharge decision 
having been made at 4 hours after initial presentation and (2) suffered no major adverse 
event (as defined below) during the following 3 months. Secondary outcomes included 
length of initial hospital stay and total inpatient days over 3 months, and major adverse 
events (death, non-fatal AMI, life-threatening arrhythmia, emergency revascularisation or 
hospitalisation for myocardial ischaemia). Economic analysis estimated mean costs and 
quality-adjusted life-years (QALYs), and then estimated the probability of cost-effectiveness 
assuming willingness to pay of £20,000 per QALY gained.
Results: We randomised 1132 participants to point of care and 1131 to standard care, 
and analysed 1125 and 1118, respectively [mean age 54.5 years, 1307/2243 (58%) male 
and 269/2243 (12%) with known coronary heart disease (CHD)]. In the point-of-care group 
358/1125 (32%) were successfully discharged compared with 146/1118 (13%) in the 
standard-care group [odds ratio (OR) adjusted for age, gender and history of CHD 3.81; 
95% confidence interval (CI) 3.01 to 4.82, p < 0.001]. Mean length of the initial hospital stay 
was 29.6 hours versus 31.8 hours (mean difference = 2.1 hours; 95% CI –3.7 to 8.0 hours, iv Abstract
p = 0.462), while median length of initial hospital stay was 8.8 hours versus 14.2 hours 
(p < 0.001). More patients in the point-of-care group had no inpatient days recorded during 
follow-up (54% vs 40%, p < 0.001), but mean inpatient days did not differ between the two 
groups (1.8 vs 1.7, p = 0.815). More patients in the point-of-care group were managed on 
coronary care [50/1125 (4%) vs 31/1118 (3%), p = 0.041]. There were 36 (3%) patients with 
major adverse events in the point-of-care group and 26 (2%) in the standard-care group 
(adjusted OR 1.31; 95% CI 0.78 to 2.20, p = 0.313). Mean costs per patient were £1217 with 
point-of-care versus £1006 with standard care (p = 0.056), while mean QALYs were 0.158 
versus 0.161 (p = 0.250). The probability of standard care being dominant (i.e. cheaper and 
more effective) was 0.888.
Conclusions: Point-of-care testing increases the proportion of patients successfully 
discharged home and reduces the median (but not mean) length of hospital stay. It is more 
expensive than standard care and unlikely to be considered cost-effective.
Trial registration: Current Controlled Trials ISRCTN37823923.
Funding: This project was funded by the NIHR Health Technology Assessment programme 
and will be published in full in Health Technology Assessment; Vol. 15, No. 23. See the HTA 
programme website for further project information.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Executive summary
Background
Patients with acute chest pain require rapid and accurate diagnostic assessment for acute 
myocardial infarction (AMI). Standard care currently involves hospital admission for 
measurement of troponin at least 12 hours after worst symptoms. As most patients do not 
ultimately have AMI this is inconvenient for patients and wastes health-care resources.
Point-of-care biomarker assessment with the combination of creatine kinase MB (mass) [CK-MB 
(mass)], myoglobin and troponin measured at presentation and 90 minutes later could potentially 
reduce the need for hospital admission and improve patient care. This combination has been 
shown to have high sensitivity for AMI, allowing earlier identification than laboratory testing and 
expedited decision-making. However, existing studies do not reliably tell us whether the panel 
would alter patient care, improve outcomes or reduce health service costs.
Objectives
We aimed to measure the effect of using a point-of-care cardiac marker panel upon successful 
discharge home after emergency department (ED) assessment, length of hospital stay, use of 
coronary care, cardiac tests and treatments, subsequent hospital attendance and/or admission, 
and major adverse events, and then estimate the cost-effectiveness of the point-of-care panel 
in terms of mean costs and quality-adjusted life-years (QALYs) accrued compared with 
standard care.
Methods
We undertook a multicentre pragmatic randomised controlled trial and economic evaluation 
of a point-of-care cardiac marker panel in the management of patients with acute chest pain in 
six EDs. We recruited people presenting to hospital with chest pain due to suspected but not 
proven AMI, and no other potentially serious alternative pathology or comorbidity. Participants 
were randomly allocated to receive either (1) diagnostic assessment using the point-of-care 
biochemical marker panel or (2) conventional diagnostic assessment without the panel. All tests 
and treatments other than the panel were provided at the discretion of the clinician. Data were 
collected from hospital records and a questionnaire mailed to participants at 1 and 3 months, 
measuring health and social care resource use, health utility [European Quality of Life-5 
Dimensions (EQ-5D)] and satisfaction with care.
The primary outcome was the proportion of patients successfully discharged home after ED 
assessment, defined as patients who had (1) either left the hospital or were awaiting transport 
home with a discharge decision having been made at 4 hours after initial presentation and 
(2) suffered no adverse event (as defined below) during the following 3 months.
Secondary outcomes were (1) length of initial hospital stay and total inpatient days over 
3 months; (2) health utility measured using the EQ-5D self-complete questionnaire at 1 and 
3 months after attendance; (3) satisfaction with care measured at 1 month after attendance 
using an 11-question self-complete Likert-scale questionnaire; (4) the proportion of patients x Executive summary
admitted to the coronary care unit, receiving cardiac medications or cardiac interventions 
(such as angiography, percutaneous intervention or bypass grafting); (5) re-attendance at, and/
or re-admission to, hospital and outpatient attendances over the following 3 months; (6) major 
adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency revascularisation 
or hospitalisation for myocardial ischaemia); and (7) the proportion of admitted patients 
ultimately diagnosed as having AMI by the universal definition.
We planned to recruit 1565 to each arm of the trial to give 80% power to detect a 5% absolute 
difference in the proportion of patients successfully discharged (55% vs 50%) and a 2% absolute 
difference in the major adverse event rate (2% vs 4%) at the two-sided significance level of 5%. 
We estimated that this could be achieved by six hospitals recruiting 550 patients each over 
12 months, assuming that 70% of those eligible were recruited. Actual patient recruitment 
was slower than anticipated and varied between 300 and 400 patients per centre per year of 
recruitment, with 35% of eligible patients recruited instead of the 70% anticipated. After 1800 
patients had been recruited, a futility analysis undertaken by the Data Monitoring Committee 
at the request of the funders suggested that there were grounds for termination on the basis of 
futility, with the trial having > 99% conditional power to detect a 5% difference in the proportion 
successfully discharged and < 10% power to detect a 2% difference in major adverse events. 
Recruitment was terminated with 2263 patients recruited.
An economic analysis was undertaken from a health and social care perspective using trial data 
to estimate the mean cost per patient of chest pain-related care and the mean number of QALYs 
accrued by patients in each arm of the trial up to 3 months after recruitment. A microcosting 
study of 30–40 participants at each site was used to obtain precise estimates of the costs of 
initial diagnostic assessment. The trial analysis was augmented with a decision-analytic model 
to explore the potential effect of differences in major adverse event rates upon long-term costs 
and outcomes.
Results
We recruited 2263 participants, of whom 2243 had usable data [mean age 54.5 years, 1307/2243 
(58%) male and 269/2243 (12%) with known coronary heart disease (CHD]. In the point-of-
care group 358/1125 (32%) were successfully discharged compared with 146/1118 (13%) in 
the standard-care group [odds ratio (OR) adjusted for age, gender and history of CHD 3.81; 
95% confidence interval (CI) 3.01 to 4.82, p < 0.001]. The effect on the primary outcome varied 
between hospitals with point-of-care panel assessment increasing successful discharges at four 
hospitals, having no effect at one and decreasing successful discharges at one. The ORs for 
successful discharge at individual hospitals varied from 0.12 (95% CI 0.01 to 1.03, p = 0.054) to 
11.07 (95% CI 6.23 to 19.26, p < 0.001).
Mean length of the initial hospital stay was 29.6 hours in the point-of-care group versus 
31.8 hours in the standard-care group (mean difference = 2.1 hours, 95% CI –3.7 to 8.0 hours, 
p = 0.462), while median length of initial hospital stay was 8.8 hours versus 14.2 hours (p < 0.001). 
More patients in the point-of-care group had no inpatient days recorded during follow-up (54% 
vs 40%, p < 0.001), but mean inpatient days did not differ between the two groups (1.8 vs 1.7, 
p = 0.815). More patients in the point-of-care group were managed on coronary care [50/1125 
(4%) vs 31/1118 (3%), p = 0.041].
There were no significant differences between the groups in the proportions receiving glyceryl 
trinitrate, heparin, glycoprotein inhibitors, antacids or beta-blockers. More patients in the 
point-of-care group received clopidogrel (21% vs 16%, p = 0.002), while more patients in © Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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the standard-care group received aspirin (60% vs 55%, p = 0.031). There were no significant 
differences in the use of non-biomarker cardiac investigations, cardiac interventions, 
re-attendances or subsequent admissions, although there were non-significant trends towards 
increased use of cardiac interventions with point-of-care that influenced cost analysis. Patients in 
the point-of-care group were slightly more likely to have a chest pain-related outpatient review 
(21% vs 18%, p = 0.05).
There were no significant differences in mean EQ-5D scores at 1 or 3 months (point-of-care 0.742 
vs standard care 0.759 at 1 month, p = 0.614, and 0.752 vs 0.759 at 3 months, p = 0.638). Most 
patients were satisfied with most aspects of their care, with only a small proportion rating their 
care as poor. Point-of-care panel assessment was favoured in two of the 10 dimensions (urgency 
of assessment and personal interest in care) and in the question rating overall care.
There were 36 patients (3%) with major adverse events in the point-of-care group and 26 (2%) 
in the standard-care group (adjusted OR 1.31, 95% CI 0.78 to 2.20, p = 0.313). The proportion of 
patients ultimately diagnosed as having AMI was 82/1125 (7.3%) in the point-of-care group and 
76/1118 (6.8%) in the standard-care group (p = 0.650).
Mean costs per patient were £1217 with point-of-care versus £1006 with standard care (p = 0.056), 
while mean QALYs were 0.158 versus 0.161 (p = 0.250). The probability of standard care being 
dominant (i.e. cheaper and more effective) was 0.888, whereas the probability of the point-of-care 
panel being dominant was 0.004.
Conclusions
Point-of-care panel assessment increases the proportion of patients successfully discharged home, 
leading to reduced median length of initial hospital stay, but no change in mean hospital stay or 
total inpatient days. Point-of-care panel assessment is associated with increased use of coronary 
care and may be associated with increased use of other interventions. Cost-effectiveness is mainly 
driven by differences in mean cost, with point estimates suggesting that point-of-care panel 
assessment is £211 per patient more expensive than standard care. It is unlikely to be considered 
cost-effective in the NHS, with a 0.888 probability that standard care is dominant.
Further research is required to identify factors that influence the effectiveness and cost-
effectiveness of point-of-care panel assessment, explore alternative ways of managing patients 
with low-risk chest pain and evaluate new cardiac biomarkers.
Trial registration
This study is registered as ISRCTN37823923.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the 
National Institute for Health Research.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 1  
Introduction
Diagnostic assessment of acute chest pain
Chest pain is responsible for around 700,000 patient attendances per year in England and Wales, 
and around one-quarter of hospital admissions.1 The main reason for attendance is the possibility 
of acute myocardial infarction (AMI). Patients with ST-elevation myocardial infarction 
(STEMI) can benefit from early coronary reperfusion using primary angioplasty or intravenous 
thrombolysis. Patients with non-ST-elevation myocardial infarction (NSTEMI), who are much 
more numerous than those with STEMI, benefit from hospital admission and treatment. The 
potential benefits of treatment for AMI have led to public awareness campaigns encouraging 
people with acute chest pain to call for emergency medical help and national guidelines 
recommending that patients with chest pain should call for an emergency ambulance to take 
them to a hospital emergency department (ED) rather than contact their general practitioner 
(GP).2 Thus, ED attendances with chest pain are increasing.
Standard initial assessment of patients with acute chest pain consists of a clinical history and 
examination, 12-lead electrocardiogram (ECG) recording and a chest radiograph. On the basis of 
this assessment around 34% will have a clinical diagnosis of suspected acute coronary syndrome 
(ACS), 11% will have an ECG diagnosis of suspected acute coronary syndrome, 19% will have 
a clear diagnosis of benign non-cardiac chest pain (such as muscular pain) and 12% will have 
suspected serious non-cardiac chest pain (such as pulmonary embolus) or comorbidity (such as 
heart failure). The remaining 24% have no clear diagnosis but have a significant risk (5–10%) of 
undiagnosed AMI.1
Acute myocardial infarction is usually diagnosed by serial cardiac biomarker testing (‘cardiac 
enzymes’) typically by measurement of troponin in the blood. A patient with ischaemic 
symptoms (such as chest pain) would be diagnosed as having AMI according to the universal 
definition for acute, evolving or recent AMI if a troponin level is recorded above the 99th 
percentile of the values for a reference control group.3 These patients are likely to benefit from 
hospital admission.4 Patients with no troponin elevation have a low risk of adverse outcome 
and are unlikely to benefit from hospital admission, unless they have a serious non-coronary 
cause for their pain (such as pulmonary embolus) or serious comorbidity (such as heart failure 
or arrhythmia). Rapid and accurate identification of patients with AMI is thus a hallmark of 
effective emergency care for chest pain.
Current recommendations suggest that patients with chest pain due to suspected, but not proven, 
AMI should receive diagnostic testing with a troponin sample taken 12 hours after symptom 
onset,5 the delay being necessary because troponin sensitivity does not reach optimal levels 
until this time. This approach is inconvenient and potentially costly because it requires many 
patients to be unnecessarily admitted to hospital until the time delay has elapsed. Most patients 
presenting to the ED with suspected AMI do not actually have subsequent confirmation of AMI, 
so their admission will ultimately prove avoidable. Economic analysis suggests that admitting 
patients for cardiac marker testing is not a cost-effective use of health service resources compared 
with early cardiac marker testing.6 Recent studies7,8 have suggested that new high-sensitivity 2 Introduction
troponin assays may be able to rule out AMI earlier than 12 hours, although the effect of using 
these assays in practice has not yet been evaluated.
Evidence also suggests that these guidelines are often not followed in a busy emergency setting 
where acute beds are limited. Collinson et al.9 showed that 7% of patients discharged after ED 
assessment for acute chest pain had elevated troponin levels at follow-up 2 days later. Goodacre 
et al.10 showed that, in the standard-care arm of a randomised trial of a chest pain unit, 14% 
of patients with an elevated troponin level at 2-day follow-up had been sent home from the 
ED. A national survey of EDs11 asked the lead consultant what proportion of patients with 
undifferentiated chest pain would be admitted to hospital. Estimates varied from less than 20% 
to over 80%. Hence, it appears that the theoretical ideal of a 12-hour troponin is not realised in 
practice and, as a result, patients are inadvertently discharged home with undetected AMI.
The point-of-care cardiac marker panel
Rapid point-of-care testing using a panel of markers offers an alternative approach that may 
be more effective and cost-effective than current practice. This technology has two elements 
that offer putative benefits: (1) point-of-care testing to reduce the turnaround time to results 
being available and (2) the use of a combination of markers, including measurement of marker 
gradients, to optimise early sensitivity. This is based on the idea that other markers, such as 
myoglobin and creatine kinase MB (mass) [CK-MB (mass)], may start to rise earlier than 
cardiac troponin.
Point-of-care testing involves using an analyser in the ED for marker assays. The analyser needs 
to be operated quickly and reliably by clinical staff. It can then allow rapid provision of marker 
results with short turnaround times to guide decision-making. Several randomised controlled 
trials (RCTs) have compared point-of-care tests with the same test performed on a laboratory 
analyser to determine whether use of point-of-care testing reduces turnaround times and changes 
practice. Collinson et al.12 showed that the use of point-of-care troponin testing on a coronary 
care unit led to reduced length of coronary care unit stay and overall hospital stay. Renaud et 
al.13 showed that point-of-care troponin testing in an ED reduced time to anti-ischaemic therapy 
and physician notification of troponin results, but did not change ED length of stay or patient 
outcomes. Ryan et al.14 evaluated point-of-care troponin testing in four EDs and found that the 
effect varied between settings, with length of stay in the ED being increased in one hospital and 
decreased in another. Kendall et al.15 evaluated a variety of point-of-care tests in an ED and found 
that point-of-care testing reduced turnaround times and times to decisions being made, but did 
not influence clinical outcomes or length of stay. Overall, therefore, there is reasonable evidence 
that point-of-care testing reduces turnaround times and possibly also times to decisions being 
made, but no consistent evidence of an effect on length of stay. One crucial component may be 
the need to incorporate point-of-care testing within a decision-making protocol.
Combining markers in a panel aims to overcome the limitations of individual markers. Different 
cardiac markers have optimal sensitivity for AMI at different times after symptom onset.16,17 
Combining markers to form a panel that is positive if any one marker is positive should optimise 
sensitivity and ensure that fewer cases of AMI are missed. Measuring the gradient rise of markers 
between baseline (when the patient arrives at hospital) and a specified time later (typically 
90 minutes) has been shown to improve early sensitivity18,19 and can also improve specificity if 
only the gradient rise (rather than the absolute value) is considered positive.
Most studies of point-of-care cardiac marker panels have evaluated the combination of CK-MB 
(mass), myoglobin and troponin I measured at presentation and 90 minutes later. These have © Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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shown that the panel has high sensitivity and can accurately rule out AMI by 90 minutes after 
presentation.20–27 This results in earlier identification of AMI than with laboratory testing22 and 
expedited decision-making with turnaround times reduced by 55%.23 Meanwhile, comparison of 
patient management with the panel with previous practice showed a 40% reduction in coronary 
care unit admissions.24
These studies show that the point-of-care combination of CK-MB (mass), myoglobin and 
troponin I measured at presentation and 90 minutes has appropriate diagnostic accuracy, but 
they do not reliably tell us whether the panel will alter patient care, improve outcomes or reduce 
health service costs. Early diagnostic accuracy and reduced turnaround times will lead to changes 
in practice only if clinicians act upon the additional diagnostic information. The before and after 
study by Ng et al.24 may be confounded by changes in coronary care referrals over time and, 
originating from the USA where coronary care usage is much higher than in the UK, may not 
be applicable to the UK NHS. To date, there have been no randomised trials comparing marker 
panels with routine practice.
Existing data therefore suggest that point-of-care cardiac markers can accelerate decision-making 
in the ED and that a panel of markers consisting of troponin, CK-MB (mass) and myoglobin, 
measured at baseline and 90 minutes later, can accurately identify patients with AMI. This 
strategy could allow rapid and accurate diagnosis in the ED or clinical decision unit, facilitating 
hospital admission for those with AMI and discharge home for those without. However, such 
a strategy needs to be evaluated in practice and compared with current management before it 
can be recommended for widespread adoption throughout the NHS. Evaluation allows us to 
determine whether clinical decision-making is changed by using the point-of-care panel, whether 
hospital admissions are actually reduced in practice, whether reduced hospital admissions save 
sufficient health service costs to compensate for the additional costs of point-of-care testing 
and whether patient outcomes are improved. In addition, advances in assay methodology 
for troponin suggest that troponin alone may be used to rule in and rule out AMI soon after 
presentation, and marker panels may be unnecessary.28 This has also not been tested in a 
randomised controlled manner.
Research objectives
We aimed to measure the effect of using a point-of-care cardiac marker panel upon the following 
outcomes in patients presenting to the ED with suspected but not proven AMI:
1.  the proportion of patients successfully discharged home after ED assessment
2.  health utility and satisfaction with care
3.  the use of coronary care beds and cardiac treatments
4.  subsequent re-attendance at and/or re-admission to hospital
5.  major adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency 
revascularisation or hospitalisation for myocardial ischaemia)
6.  health and social care costs.
In addition, we planned to undertake secondary analysis of the data of the Randomised 
Assessment of Treatment using Panel Assay of Cardiac markers (RATPAC) trial to evaluate the 
TIMI (thrombolysis in myocardial infarction)29 and GRACE (Global Registry of Acute Coronary 
Events)30 clinical prediction scores and store blood samples taken from participants in the 
intervention arm to evaluate potential new or alternative markers. The results of the evaluation 
of TIMI and GRACE scores are presented in this report. Funding has been sought to undertake 
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Chapter 2  
Methods
Study design
We undertook a multicentre pragmatic RCT and economic evaluation of a point-of-care cardiac 
marker panel in the management of patients with suspected, but not proven, AMI in six EDs in 
the UK.
Setting
The participating hospitals were Barnsley District General Hospital, Derriford Hospital in 
Plymouth, Edinburgh Royal Infirmary, Frenchay Hospital in Bristol, Leeds General Infirmary 
and Leicester Royal Infirmary. They were selected to provide a range of different settings that 
reflected the variation in current NHS practice and the variation in facilities available to manage 
patients with acute chest pain. Table 1 outlines the characteristics of the participating centres.
Participants
We recruited people presenting to the ED with chest pain due to suspected but not proven AMI 
in whom a negative point-of-care marker test could potentially rule out AMI and allow discharge 
home. All patients with chest pain were considered for participation but then excluded if they 
met any of the following criteria:
1.  Diagnostic ECG changes for AMI or high-risk acute coronary syndrome (> 1 mm ST 
deviation or > 3 mm inverted T waves). These patients are at high risk of adverse outcome 
and require inpatient care even if marker tests are negative.
2.  Known coronary heart disease (CHD) presenting with prolonged (> 1 hour) or recurrent 
episodes of typical cardiac-type pain. These patients have unstable angina and require 
inpatient care for symptom control even if marker tests are negative.
TABLE 1  Characteristics of the participating centres
Annual ED 
attendances: 1 April 
2008 to 31 March 2009
No. of acute 
medical bedsa ED facilities On-site cardiology services
Barnsley 71,678 462 – CCU, rapid access clinic
Derriford 85,341 240 CDU CCU, angioplasty, cardiac surgery, rapid access clinic
Edinburgh 105,378 843b – CCU, angioplasty, cardiac surgery, rapid access clinic
Frenchay 62,823 461 CDU CCU, angioplasty
Leeds 109,362 491 CDU CCU, angioplasty, cardiac surgery, rapid access clinic
Leicester 156,053 290 – CCU, rapid access clinic
CCU, coronary care unit; CDU, clinical decision unit.
a  Excluding escalation beds.
b  Breakdown for medical beds not available, so all acute beds reported.6 Methods
3.  Proven or suspected serious non-coronary pathology (e.g. pulmonary embolus) that requires 
inpatient care even if AMI is ruled out.
4.  Comorbidity or social problems that require hospital admission even if AMI can be 
ruled out.
5.  An obvious non-cardiac morbidity (e.g. pneumothorax or muscular pain) in a patient 
in whom AMI can be excluded as a possible cause without resorting to further 
diagnostic testing.
6.  Presentation more than 12 hours after the most significant episode of pain, in which case 
a single troponin measurement would clearly be more appropriate than point-of-care 
panel assessment.
7.  Previous participation in the RATPAC trial.
8.  Inability to understand the trial information owing to cognitive impairment.
9.  Non-English-speaking patients for whom translation facilities were not available.
For every fourth week of trial recruitment the research nurse at each hospital examined ED 
attendance lists to identify patients attending with chest pain and record basic demographic 
details and reasons for exclusion. The huge number of attendances with chest pain meant that 
undertaking this process throughout the whole trial would have produced an excessive workload, 
whereas monitoring every fourth week achieved the aim of reporting sample selection within 
acceptable use of resources.
Recruitment and randomisation
Research nurses and ED staff identified eligible patients, provided trial information and obtained 
written consent. Participants were then randomly allocated to receive either (1) diagnostic 
assessment using the point-of-care biochemical marker panel or (2) conventional diagnostic 
assessment without the panel.
The Nottingham Clinical Trials Unit (CTU) generated a simple randomisation sequence, 
stratified by centre, which was not revealed to any person involved in patient recruitment. 
Recruiting doctors and research nurses accessed a secure website provided by Nottingham CTU 
and entered participant details. The CTU revealed the participant’s allocated treatment group to 
the ED only after the participant’s details were entered, written consent was confirmed and the 
participant irrevocably entered into the trial.
Planned interventions
Participants were randomised to receive either:
  ■ diagnostic assessment using the point-of-care biochemical marker panel
or
  ■ conventional diagnostic assessment without the panel.
The only difference between the two arms of the trial was that patients in the intervention arm 
received assessment with the point-of-care panel. The use of all other tests and treatments, and 
decision-making in the ED, was at the discretion of the attending clinician.
The point-of-care cardiac marker panel comprised CK-MB (mass), myoglobin and troponin I, 
measured at presentation and 90 minutes later, using the Siemens Stratus CS Analyser (Dade 
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interpretation of the results. We provided a recommended protocol that advised a first panel 
test immediately after initial ED assessment and a second panel test 90 minutes later, and then 
advised hospital admission or discharge on the basis of point-of-care results (Appendix 1). 
Decisions were ultimately at the discretion of clinical staff. We did not police the use of the point-
of-care protocol to ensure that it was being followed.
Other than obtaining consent, collecting data and random allocation to use of the point-of-care 
test, the only change to routine practice was that we asked clinical staff to take an additional 
sample of blood for storage (without repeating venepuncture) each time a point-of-care 
blood sample was required. The additional blood sample taken after point-of-care testing was 
transported to the hospital laboratory to be centrifuged and the serum separated and then frozen. 
Batches of frozen samples were then transported quarterly to St George’s Hospital for longer-term 
storage and future secondary analysis of new biomarker assays.
The RATPAC trial was a pragmatic trial, intended to determine whether point-of-care panel 
assessment should be standard practice for patients presenting to the ED with suspected AMI. It 
was designed to compare two pragmatic alternatives (management with and without point-of-
care panel assessment) under routine conditions to determine whether use of the test changes 
costs or outcomes. This pragmatic design had the following implications:
1.  There was no attempt to blind clinical staff, patients or carers to the allocated treatment 
group after randomisation.
2.  The point-of-care test was provided with a recommended protocol for use but management 
decisions were ultimately at the discretion of the clinical staff.
3.  All other diagnostic tests and the use of laboratory blood tests in the control group were at 
the discretion of the clinical staff. Blood samples were taken only for the purposes of clinical 
management. We did not take blood samples at additional time points to evaluate theoretical 
management strategies or to evaluate the accuracy of diagnostic assessments. The blood 
samples taken for storage and future analysis were taken at the same time as the point-of-care 
samples used for clinical care and did not require additional venepuncture.
Point-of-care assays and analyser
Cardiac troponin I, CK-MB (mass) and myoglobin were measured by point-of-care testing 
in the ED on the Stratus CS Analyser. The original project protocol planned to use the Biosite 
Triage analyser (Biosite, San Diego, CA, USA), as this was the most widely used analyser at the 
time of protocol development. However, as protocol development continued it became apparent 
that new-generation high-sensitivity troponin assays, as well as point-of-care analysers with 
high-sensitivity troponin assays, were becoming available.31 Discussions with experts in the 
field revealed reservations about the analytical performance of the Biosite system, particularly 
the analytical sensitivity of its troponin assay. In view of this, and the need to ensure the future 
generalisability and the development towards more sensitive troponin assays, it was deemed 
prudent to use a more sensitive system in the trial. Recent publications7,8 have since confirmed 
the potential of high-sensitivity troponin assays to improve early assessment.
The Stratus CS Analyser was selected on the basis of having most data as an instrument suitable 
both for the emergency laboratory and for use as a point-of-care instrument,32–34 as well as a 
troponin assay with performance characteristics close to current recommendations for analytical 
goals. It has the advantage that it can measure troponin, myoglobin and CK-MB (mass) on the 
same sample.35 In addition, it has the health and safety advantages of using a closed system that 
does not require the operator to open the blood tube and pipette the sample on to a test strip.8 Methods
Blood is drawn directly into a Vacutainer tube (a standard no-touch aseptic blood-sampling 
system) using lithium heparin as an anticoagulant. The tube is then inverted twice to mix the 
blood and anticoagulant. It is then ready for analysis. The sample is introduced directly into the 
machine, the sample door closed and analysis is fully automatic.
The analytical characteristics of the assays were as follows. Cardiac troponin I: detection 
limit 0.02 µg/l, analytical range 0.02–50 µg/l, interassay coefficient of variation (CV) 4.3–5.1% 
(0.03–0.22 µg/l). The 99th centile of the assay is 0.07 µg/l. Myoglobin: detection limit 1 µg/l, 
analytical range 1–900 µg/l, interassay CV 1.9–12.7% (56–308 µg/l); 95% reference interval, males 
21–98 µg/ml, females 19–56 µg/l, combined 20–82 µg/l. CK-MB (mass): detection limit 0.3 µg/l, 
analytical range 0.3–150 µg/l, interassay CV 0.15–1.27% (3.7–39.3 µg/l); 95% reference interval 
0.6–3.5 µg/l.
The recommended point-of-care protocol
The point-of-care protocol is outlined in Appendix 1. The sample(s) were deemed positive and 
hospital admission advised if any of the following were met:
1.  any CK-MB (mass) exceeded 5 µg/l
2.  the CK-MB (mass) gradient exceeded 1.6 µg/l
3.  the myoglobin gradient increase exceeded 25% of the baseline value
4.  troponin exceeded 0.02 µg/l.
The CK-MB (mass) gradient is based on data from Fesmire et al.,18,19 suggesting that this value 
allows optimisation of both sensitivity and specificity. The myoglobin gradient was used alone 
because absolute myoglobin levels have very poor specificity, whereas using only the gradient rise 
maintains the value of early sensitivity without compromising specificity.
The Stratus CS Analyser is able to detect troponin levels in the range of 0.03–0.07 µg/l even 
though this is below the 99th centile of normal, which is conventionally used as a diagnostic 
threshold. Our understanding of the significance of very low troponin levels developed during 
the trial and is continuing to develop now (indeed we anticipate that secondary analysis of 
RATPAC blood samples will provide a further contribution). At the start of the trial we decided 
to err on the side of caution and recommended that any detectable troponin above 0.02 µg/l 
should be considered positive in case it represented the start of a significant rise. However, it 
became apparent from emerging data that levels between 0.03 and 0.07 µg/l do not typically 
represent an early troponin rise and where they do this is evident upon measuring the difference 
between baseline and 90-minute values. We therefore amended the guidance to recommend that 
the tests only be considered positive on the troponin assay if:
  ■ any troponin level exceeded 0.07 µg/l
or
  ■ the initial troponin is below 0.03 µg/l and the second sample is above 0.02 µg/l.
The new guidance was disseminated and implemented between December 2008 and 
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Standard care
The standard-care group were managed without point-of-care panel assessment according to 
existing guidance for management of low-risk chest pain due to suspected ACS at each of the 
participating hospitals. We deliberately selected a variety of hospitals that were operating a range 
of different strategies and had a variety of different facilities available for chest pain management. 
Table 2 summarises the location of care and biomarker(s) used for low-risk patients in each 
hospital. Patients were referred to the cardiology team if biomarkers were positive and discharged 
(with or without exercise treadmill testing) if negative.
Outcome measures
The primary outcome was the proportion of patients successfully discharged home after ED 
assessment. To be considered successfully discharged the patient had to have both (1) left the 
hospital or be awaiting transport home with a discharge decision having been made at 4 hours 
after initial presentation and (2) suffered no major adverse event (as defined below) during the 
following 3 months.
Secondary outcomes were:
1.  Health utility measured using the European Quality of Life-5 Dimensions (EQ-5D) self-
complete questionnaire at 1 and 3 months after attendance.
2.  Satisfaction with care measured at 1 month after attendance using a modified Group Health 
Association of America questionnaire that had been used successfully in previous studies of 
diagnostic strategies for acute chest pain.10,36
3.  The proportion of patients admitted to the coronary care unit, receiving cardiac medications 
(aspirin, heparin, clopidogrel or glycoprotein IIb/IIIa inhibitors) or receiving cardiac 
interventions [angiography, percutaneous coronary intervention (PCI) or bypass grafting].
4.  Length of initial hospital stay and total inpatient days over 3 months.
TABLE 2  Existing management strategies for low-risk chest pain
Location Troponin assay
Troponin 
threshold used 
(µg/l) Laboratory analyser
Timing of 
troponin 
(hours)a Other biomarkers
Barnsley Inpatient ward Siemens Centaur 
Troponin I Ultra
< 0.20 Siemens Centaur XP 12
Derriford CDU Roche Troponin T < 0.01 Roche Modular E170 6
Edinburgh Medical 
Assessment 
Unit
Abbott STAT 
Troponin I
< 0.05b Architect i2000SR 12 Creatine kinase
Frenchay CDU Beckman Coulter 
Access Accu 
Troponin I
< 0.06 Beckman Coulter 
Access 2
12
Leeds CDU Siemens Centaur 
Troponin I Ultra
< 0.05 Siemens Centaur XP 12
Leicester Inpatient ward Siemens Centaur 
Troponin I Ultra
< 0.06 Siemens Centaur XP 12 Creatine kinase
CDU, clinical decision unit.
a  Timing after onset of worst symptoms.
b  Changed from < 0.2 µg/l on 21 January 2009.10 Methods
5.  Re-attendance at and/or re-admission to hospital and outpatient attendances over the 
following 3 months.
6.  Adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency 
revascularisation or hospitalisation for myocardial ischaemia).
7.  The proportion of admitted patients ultimately diagnosed as having AMI by the 
universal definition.3
We selected successful discharge home as the primary outcome because the main purpose of 
point-of-care cardiac marker testing in this patient group is to facilitate discharge home. This 
outcome is beneficial for patients, who avoid the inconvenience and risks of hospital admission, 
and is beneficial for the health service, which avoids unnecessary admissions and pressure 
upon acute and emergency services. Patients who suffered an adverse event after discharge were 
not classified as a successful discharge home because they may have benefited from hospital 
admission. We also recorded the proportion of admitted patients who were ultimately diagnosed 
as having AMI to provide a measure of the appropriateness of admissions.
Assessment of outcomes
Recruiting staff recorded baseline data (including the variables required to calculate the TIMI 
or GRACE score), the results of initial assessment (including any biochemical cardiac tests) 
and admission or discharge from the ED. Research nurses then used ED and hospital inpatient 
notes to record management decisions at initial attendance and admission, extract resource 
use data and identify subsequent attendances/admissions and adverse events up to 3 months. 
Time and date of discharge for the initial admission were recorded as precisely as possible using 
computer records, case notes and contact with hospital staff. The total number of inpatient days 
over 3 months was recorded using hospital notes. An inpatient day was defined as being an 
overnight stay.
Research nurses checked patient status (dead or alive) at 1 and 3 months, using hospital 
information systems. Deceased patients were assumed to have a score of zero on EQ-5D and 
were excluded from other patient-based assessments. Participants who were not recorded as 
dead were mailed a questionnaire at 1 and 3 months from the University of Sheffield to identify 
adverse events and hospital attendances, health and social care resource use, and measure EQ-5D 
and satisfaction with care (satisfaction at 1 month only). Our previous study suggested a 70–80% 
response rate to this questionnaire.10,37
A single reviewer (SG) blinded to treatment group classified all ED re-attendances, subsequent 
hospital admissions and outpatient reviews as either potentially chest pain related (including 
non-cardiac conditions that could have initially presented as chest pain) or clearly non-chest pain 
related (such as limb injuries).
The initial working diagnosis and final diagnosis were recorded and categorised by the research 
nurse, based upon the diagnosis recorded in the notes by the most senior clinician at the end of 
initial ED assessment and at the end of hospital admission, respectively. Patients were classified 
as having AMI on the basis of the presence of a rise in their troponin level above the diagnostic 
threshold of the relevant assay and absence of a final diagnosis of an alternative condition (such 
as sepsis or pulmonary embolism) that could have produced a troponin elevation. Patients with 
a troponin rise consistent with AMI and final diagnosis of ACS or ‘other AMI’ were classified 
as having AMI. Patients with no troponin rise and a final diagnosis that was not ACS or ‘other 
AMI’ were classified as not having AMI. A single reviewer blinded to treatment group reviewed 
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and categorised these patients as having AMI if an ECG showed ST elevation and coronary 
reperfusion was performed, otherwise they were categorised as having no AMI. Two independent 
reviewers blinded to treatment group reviewed case details of all patients with a troponin rise 
and a final diagnosis other than ACS or ‘other AMI’, and all patients with a troponin rise that was 
inconsistent with AMI (e.g. if a positive troponin was shortly followed by a negative troponin 
result). Each decided whether AMI was the most likely diagnosis. Disagreements were resolved 
by discussion and patients classified as having AMI or no AMI.
Proposed sample size
We planned to recruit 3130 participants to the trial. A previous randomised trial in this patient 
group suggested that around 50% of the control group would be successfully discharged.10 
With 1565 evaluable subjects in each arm of the trial we expected to have 80% power to detect 
a 5% absolute difference in the primary outcome (50% vs 55%) at the two-sided significance 
level of 5%. The same sample size provided 80% power to detect a 2% absolute difference (2% 
vs 4%) in major adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency 
revascularisation or hospitalisation for myocardial ischaemia), again at the two-sided 5% level 
of significance.
We estimated that we would require six hospitals to recruit for 12 months each to achieve the 
sample size of 3130, assuming that we recruited 70% of those eligible. Previous studies of this 
specific patient group undertaken by our team had shown that recruitment of 550 suitable 
patients per year is attainable at a typical hospital.10,37–39
Previous studies had also shown a response rate of 70–80% for postal questionnaires,10,37 thus 
providing an effective sample size of at least 1000 in each of the two groups to evaluate health 
utility, satisfaction with care and health service resource use.
Statistical analysis
We planned to analyse the primary outcome through logistic regression, fitting concurrently with 
intervention group the effect of centre and appropriate baseline measures (including age, gender 
and past history of CHD), to present adjusted odds ratios (ORs) along with their corresponding 
95% confidence intervals (CIs). A similar analysis was used for adverse events. Primary analysis 
was on an intention-to-treat basis. Secondary analysis excluded those who were not managed 
according to their allocated strategy.
We undertook a descriptive assessment to explore whether use of biochemical cardiac markers 
or admission rates changed over time in either the intervention or control group, either as a 
result of staff ‘learning curves’ in the intervention group or as a result of contamination of the 
control group.
For each patient, GRACE and TIMI scores were calculated. Two approaches were undertaken 
for calculating each score: one using the first available troponin sample and the second using the 
highest troponin level taken during the initial hospital stay. Some patients did not have all of the 
data items that were required to permit calculation of the score so two analyses were undertaken: 
one including only cases with complete data, the other including all cases with imputation to 
complete the data set. Imputation involved assuming that missing variables would be negative or, 
where appropriate, the mean value for the RATPAC population (e.g. continuous variables used 
in the GRACE score). We evaluated the predictive value of GRACE and TIMI by calculating the 12 Methods
proportion with an adverse outcome at 1 and 3 months in each quintile of GRACE score and 
each TIMI category. We then calculated the area under the receiver-operator characteristic curve 
(c-statistic) for each score.
Economic evaluation
Economic evaluation was undertaken alongside the trial using recommended practice.40 In 
addition, a cost-effectiveness model was developed to duplicate the trial results (as a way of 
validation) and extrapolate the results to longer follow-up periods. The NHS perspective was 
undertaken and other methods were in line with National Institute for Health and Clinical 
Excellence (NICE) Technology Appraisal Guidelines.41
Resource use data were collected for all patients covering the length of time in the ED, the use of 
diagnostic tests, admissions, re-admissions, outpatient reviews and cardiac procedures. Cost and 
outcome data were collected using patient notes and self-completed questionnaires as described 
previously. A small microcosting study of 30–40 patients was carried out at each site, gathering 
data on staff times relating to the care of patients. ED cost per minute was based on a study 
previously undertaken by the investigators,10 and amended using the microcosting data from 
this study. Panel costs were based on purchase price, and the remaining costs were valued using 
national unit costs.42,43 Total NHS costs up to 3 months after initial attendance were calculated. 
Quality-adjusted life-years (QALYs) were calculated by the trapezium rule using the EQ-5D tariff 
values at all follow-up points.
Economic analysis
Both cost and QALY analysis compared bootstrap estimates of the mean cost per patient of 
the two groups. Cost-effectiveness analysis estimated the incremental cost per QALY of using 
point-of-care cardiac marker testing compared with management without point-of-care panel 
assessment. Results were plotted on the cost-effectiveness plane and then transformed into 
cost-effectiveness acceptability curves with their associated frontier.44 A sensitivity analysis was 
undertaken to include production losses as reported by the patient.
We anticipated that some of the resource use and QALY data would be incomplete (missing). 
Thus, in order to maximise the information collected from the trial, we imputed missing values 
using multiple imputation within Stata (StataCorp LP, College Station, TX, USA).45 The idea of 
multiple imputation draws from the fact that missing values from incomplete data are unknown 
and the technique of multiple imputation imputes more than one likely value for the missing 
data; hence, providing an unbiased representation of uncertainty.46 Thus, an additional set of 
results is available from the imputed cost and QALY data.
Decision-analytic model
We constructed a decision-analytic model to describe the care observed in the trial, and likely 
care pathways subsequent to it. This allowed us to systematically investigate the impact of 
subsequent costs, quality of life and survival. These values were initially based on population 
norms, but then replaced with literature review estimates where appropriate. Finally, they 
were replaced by RATPAC trial estimates where required. The decision-analytic model 
was probabilistic, but with conventional sensitivity analysis used to assess the impact of 
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The main purpose of the decision-analytic model was to explore the potential impact of changes 
in the major adverse event rate upon cost-effectiveness. We anticipated that the trial would have 
adequate power to detect economically important differences in resource use and EQ-5D, but 
would only have limited power to detect differences in major adverse events. It was therefore 
possible that an intervention could be apparently cost-effective (in terms of reducing costs and 
increasing health utility), while being associated with a statistically non-significant increase in 
adverse events. The decision-analytic model was intended to explore whether uncertainty around 
the effect of the intervention upon the major adverse event rate could influence the potential 
cost-effectiveness of the intervention.
The decision-analytic model used trial data to estimate costs and QALYs up to 3 months. Beyond 
this, we used lifetime cost and QALY estimates from a previous economic analysis of a similar 
population.48 The mean lifetime cost of care for a patient with CHD was estimated to be £10,079 
[standard error (SE) = £2200] and mean QALYs accrued were estimated to be 6.829 (SE = 0.34), 
while estimates of £0 and 20 QALYs [standard deviation (SD) = 5] were used for patients without 
CHD. Trial data were used to estimate the rates of death and non-fatal AMI by 3 months after 
management with the point-of-care panel and standard care. We then assumed that those who 
had died by 3 months would accrue no further costs or QALYs, while those who survived with 
non-fatal AMI would accrue costs and QALYs associated with CHD. Probabilistic sensitivity 
analysis was then used to estimate the mean lifetime costs and QALYs of patients in the two arms 
of the trial.
The decision-analytic model was developed and implemented in an Excel (Microsoft 
Corporation, Redmond, WA, USA) spreadsheet, which included a Visual Basic macro to 
implement the replication of outcomes from the model. The results presented were based on 
10,000 outcome simulations. The pathways through the model described (1) the choice of 
diagnostic tool, using either point-of-care tests or standard-care approaches; (2) the disposal 
from the ED, either to admission or to discharge; (3) possible interventions or care once a 
positive diagnosis of ACS (and therefore admission) was made, including coronary artery bypass 
graft (CABG), PCI, thrombolysis, hospital stay with no intervention or thrombolysis treatment, 
and discharge without intervention in the case of a negative updated diagnosis, or death from 
ACS while in hospital; and (4) possible ACS events after discharge without diagnosis from the 
ED, which resulted in subsequent admission and treatment according to the treatments outlined 
in (3). Costs were accrued as simulated patients passed through the various stages in the model, 
and benefits were accrued at the end of each passage. Once discharged, either from ED or after 
admission, costs were assumed to be unaffected by the choice of diagnostic technique, and 
therefore costs of follow-up care or intervention were combined across both arms.
Ethical arrangements
All participants were asked to provide written, informed consent. Although participants were 
recruited in an emergency setting and there was only a limited amount of time available for 
considering trial information, the nature of the selected group (in particular the exclusion 
of people clearly requiring hospital treatment) ensured that eligible patients would not be 
incapacitated by their medical condition. We did not therefore make provision for recruitment of 
incapacitated patients by personal or professional legal representatives.
Ethical approval was granted by Leeds East Research Ethics Committee and review provided by 
the local research ethics committee (LREC) at each participating centre. The trial was conducted 
in accordance with Medical Research Council (MRC) Guidelines for Good Clinical Practice in 
Clinical Trials.49 The University of Sheffield was the sponsor for the trial. The Trial Steering 14 Methods
Committee (TSC) consisted of the Chief Investigator (SG), one of the co-applicants (PC), an 
independent chair (MF), two independent members (SH, JK) and a consumer representative 
(EH). We also invited a representative of the funder to join the committee but this was declined. 
The Data Monitoring and Ethics Committee (DMEC) consisted of an independent statistician 
(HT), emergency physician (WT) and cardiologist (JG), who were asked to review trial data 
at regular intervals and implement stopping rules in accordance with MRC guidance. The 
Trial Management Group (TMG) consisted of the Chief Investigator, co-applicants, Principal 
Investigator at each site, project manager, statistician, health economist and research nurses.
Data management
Trial data were collected on the case report form and follow-up form and then entered by the 
research nurses into an online database provided on a secure central server by the Sheffield CTU. 
The system had a full electronic audit trail. Quality control procedures were applied to validate 
the trial data. The project manager undertook quarterly data monitoring visits to each site, at 
which a random sample of data forms were checked for errors and validated against source 
documents. Any errors, protocol deviations or violations were reviewed with the research nurse 
and Principal Investigator and documented in the site files and master file. Central monitoring 
involved flagging discrepant or questionable data. Error reports were generated where data 
clarification was required. Monthly outputs were generated for the TMG and TSC summarising 
baseline characteristics of patients recruited, follow-up rates, data completion and adverse 
events by study site, but not study group. Outcome data summaries were provided for closed 
meetings of the DMEC. All activities were performed in accordance with Sheffield CTU standard 
operating procedures.
Trial progress
The project started on 1 April 2007. We planned to recruit staff and gain ethical and local 
governance approvals in months 1–6, recruit patients in months 7–18 and complete follow-up, 
data analysis, writing-up and dissemination in months 19–24. Actual trial progress was slower 
than anticipated: staff recruitment, ethics and regulatory approvals took up to 12 months to 
complete, patient recruitment was slower than expected, and the trial was terminated before the 
target of 3130 patients was recruited. The Gantt chart in Figure 1 outlines the planned and actual 
trial progress.
Table 3 shows the timing of processes at the six participating centres.
The reasons for the set-up phase being longer than expected are as follows:
1.  The process of drawing up contracts between the sponsor (the University of Sheffield) and 
the six participating hospitals took longer than expected.
2.  Local ethics and regulatory approvals could not be processed at some sites until contracting 
had been completed.
3.  The time taken to provide local ethics and, in particular, governance approvals varied 
between hospitals.
4.  In addition to trial training, some of the participating hospitals required all staff involved 
in the trial, including recruiting doctors, to have received formal training in Good Clinical 
Practice (GCP), even though the RATPAC trial was not a trial of an investigational 
medicinal product.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Patient recruitment was slower than anticipated and varied between 300 and 400 patients per 
centre per year of recruitment, compared with the expected 550 per centre per year. Details of 
patient recruitment are reported below (see Results) but it appeared that failure to achieve the 
expected recruitment rate was due to failure to recruit the expected proportion of eligible patients 
rather than any lack of eligible patients. Overall 35% (604/1719 – see Table 4) of eligible patients 
were recruited instead of the 70% anticipated. The following factors are likely to have accounted 
for this difference:
1.  The requirement for GCP training resulted in doctors being unwilling to assist with trial 
recruitment. This varied between centres, depending upon the local regulatory requirements. 
In one centre the need for all doctors to receive formal GCP training resulted in most 
patients being recruited by research nurses. This centre recruited the lowest proportion of 
eligible patients (19%).
2.  Service commitments, particularly the target of discharging 98% of patients from the ED 
within 4 hours of arrival, discouraged ED staff from recruiting patients during busy times.
3.  The recall of point-of-care testpaks (described below) may have reduced the confidence of 
ED staff in the technology and thus their willingness to recruit patients to the trial.
FIGURE 1  Gantt chart of trial timetable and progress.
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TABLE 3  Set-up process at each site
Site
Contract signed 
with Sheffield
Memorandum of 
Understanding 
signed with 
Siemens
Approved by 
LREC
Approved by 
Hospital Research 
Office
Research nurse 
appointed
Recruitment 
started
Barnsley 6 August 2007 14 September 2007 7 June 2007 22 May 2007 1 October 2007 30 January 2008
Derriford 22 November 2007 3 January 2008 5 July 2007 4 January 2008 26 November 2007 25 February 2008
Edinburgh 28 August 2007 4 December 2007 11 June 2007 15 June 2007 14 January 2008 2 April 2008
Frenchay 22 November 2007 23 October 2007 18 July 2007 28 November 2007 9 January 2008 31 March 2008
Leeds 9 September 2007 17 September 2007 5 July 2007 18 June 2007 3 March 2008a 16 April 2008
Leicester 1 October 2007 5 October 2007 25 June 2007 19 September 2008 14 January 2008 25 March 2008
a  Research nurse initially appointed 1 October 2007, but resigned before recruitment started.16 Methods
Changes to protocol and other unanticipated events
A number of unanticipated events occurred during the trial, two of which resulted in changes 
to the protocol. Most of the unanticipated events related to the intervention being evaluated. 
Point-of-care cardiac markers are a developing technology and clinicians are learning more about 
the technology as it is implemented. Even mature technologies can be subject to unanticipated 
problems, especially if used by a wide range of staff in a variety of settings.
The unanticipated events were:
1.  change of the point-of-care analyser
2.  recall of point-of-care testpaks
3.  amendment of the point-of-care protocol
4.  early termination of trial recruitment.
The first and third of these resulted in changes to the protocol. In addition, we became aware that 
we had not included life-threatening arrhythmia as a major adverse event in the trial protocol, 
although it was included as such in the case report form. We therefore amended the protocol to 
include life-threatening arrhythmia as a major adverse event.
Change of the point-of-care analyser
This occurred during protocol development and before the trial started. Details and the reasons 
for this are outlined above (see Point-of-care assays and analyser).
Recall of point-of-care testpaks
Siemens informed the RATPAC research team on 4 July 2008 of the need to recall point-of-care 
assays for troponin I because of a faulty batch that could have produced low false-positive levels. 
All six sites were affected, resulting in a suspension of recruitment at all sites for up to 1 week 
between 4 and 14 July 2008 until new assays were delivered. A meeting was held with Siemens 
and the biochemical expert on the Research Team (PC) to address concerns. It was concluded 
that quality assurance was tight, particularly with high-risk tests, so this would be a rare rather 
than a common occurrence. It was also discussed in length at a TMG meeting in July 2008. It was 
agreed that patients with a potentially false-positive point-of-care troponin result would have 
received appropriate follow-up based on their 12-hour troponin level and clinical condition, and 
therefore no additional intervention was required.
Amendment of the point-of-care protocol
Details and the reasons for this are outlined above (see The recommended point-of-care protocol).
Early termination of trial recruitment
Owing to the set-up delays and slower than anticipated recruitment, a request for additional 
funding was submitted to allow completion of the trial. The DMEC undertook a futility analysis 
(Appendix 2). This showed that the conditional power for the primary outcome recalculated © Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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using data to May 2009 was > 99.9% and the conditional power against major cardiac events was 
< 10%. In the light of this analysis, the trial funder declined the request for additional funding, 
based on clear efficacy (primary outcome) and futility (major cardiac events), and, consequently, 
trial recruitment was terminated on 2 June 2009, with a total of 2263 patients recruited. The 
findings reported here represent those as accrued at the point at which this decision to halt the 
trial was taken.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 3  
Results
Screening, recruitment, randomisation and follow-up
Patients were recruited between 30 January 2008 and 2 June 2009. Table 4 summarises the 
process of screening and recruitment at each centre. All hospitals stopped recruitment on 2 June 
2009 but the staggered start meant that some recruited for more days than others. Overall, 2263 
patients were recruited over a total of 2658 hospital-days (0.9 patients per day). The total at each 
site ranged from 327 to 469, and the recruitment rate ranged from 0.7 to 1.1 per day.
TABLE 4  Screening and recruitment
  All centres Barnsley Derriford Edinburgh  Frenchay Leeds Leicester
Recruitment
No. of days recruiting 2658 490 464 427 429 413 435
No. of patients recruited 2263 327 328 457 469 353 329
No. of patients recruited/day 0.9 0.7 0.7 1.1 1.1 0.9 0.8
Screeninga
No. of days screening 667 124 135 106 102 92 108
No. of patients screened 9109 1164 1632 1769 662 1760 2122
No. of patients screened/day 13.7 9.4 12.1 16.7 6.5 19.1 19.6
No. (%) of patients recruited 604 (7) 83 (7) 93 (6) 123 (7) 111 (17) 90 (5) 104 (5)
No. (%) of patients not recruited 8505 (93) 1081 (93) 1539 (94) 1646 (93) 551 (83) 1670 (95) 2018 (95)
Reason for non-recruitment [n, (%)]
Diagnostic ECG changes 1295 (14) 74 (6) 153 (9) 221 (12) 137 (21) 401 (23) 309 (15)
Known CHD with prolonged/
recurrent episodes
1378 (15) 232 (20) 456 (28) 271 (15) 58 (9) 150 (9) 211 (10)
Proven/suspected serious non-
coronary pathology
724 (8) 54 (5) 186 (11) 60 (3) 37 (6) 219 (12) 168 (8)
Comorbidity or social problems 
requiring admission
414 (5) 9 (< 1) 70 (4) 223 (13) 5 (< 1) 70 (4) 37 (2)
Obvious non-cardiac 2506 (28) 407 (35) 369 (23) 488 (28) 210 (32) 431 (24) 601 (28)
Presented > 12 hours after most 
significant pain
465 (5) 13 (1) 45 (3) 182 (10) 10 (2) 53 (3) 162 (8)
Previous participant 21 (< 1) 1 (< 1) 3 (< 1) 3 (< 1) 2 (< 1) 8 (< 1) 4 (< 1)
Unable to understand trial 
information
109 (1) 16 (1) 23 (1) 26 (1) 9 (1) 3 (< 1) 32 (2)
Non-English speaking 29 (< 1) 2 (< 1) 7 (< 1) 7 (< 1) 4 (< 1) 0 9 (< 1)
Refused consent 40 (< 1) 2 (< 1) 4 (< 1) 8 (< 1) 1 (< 1) 8 (< 1) 17 (< 1)
Eligible but recruitment not sought 1115 (12) 265 (23) 171 (10) 60 (3) 37 (6) 148 (8) 434 (20)
Prisoner 8 (< 1) 0 1 (< 1) 2 (< 1) 0 4 (< 1) 1 (< 1)
Other 161 (2) 6 (< 1) 14 (< 1) 29 (2) 20 (3) 60 (3) 32 (2)
Unknown 240 (3) 0 37 (2) 66 (4) 21 (3) 115 (7) 1 (< 1)
a  Screening was undertaken only on every fourth week of the trial.20 Results
Research nurses screened 9109 chest pain attendances on a total of 667 hospital-days during the 
trial (13.7 patients per hospital per day). Overall, 1719/9109 (19%) were eligible for recruitment 
(2.6 per hospital per day), of whom 604/1719 (35%) were recruited. The proportion of eligible 
patients recruited varied across the sites from 19% to 75%.
The proportions excluded for each exclusion criterion were as follows: 14% had ECG changes, 
15% had known CHD with prolonged or recurrent pain, 8% had suspected serious non-CHD 
pathology, 5% had comorbidities or social problems, 28% had obvious non-cardiac pain, 5% 
presented > 12 hours since their worst pain, < 1% had previously participated in the trial, 2% were 
unable to understand the trial information owing to cognitive impairment or being non-English 
speaking, 2% had other exclusion criteria, 3% had an unknown reason for exclusion and < 1% 
declined consent. These proportions varied across the sites. We were unable to verify whether this 
was due to differences in coding and classification, or differences in population characteristics.
Figure 2 shows the flow of patients through the trial after recruitment and Table 5 shows 
withdrawals and losses to follow-up. We intended to follow up patients who were recruited in 
error, provided they did not withdraw their consent, so that all consented patients could be 
analysed as randomised. However, six patients (three in each group) were not followed up after 
being recruited in error for specific reasons necessitating their exclusion (prisoners, who were 
defined as ‘vulnerable groups’, n = 3; clinician error, n = 2; and recruitment when the trial was 
suspended, n = 1). In the point-of-care group seven patients withdrew or were lost to follow-up 
before any outcomes were recorded, and a further 18 withdrew or were lost to follow-up by 
the end of the trial. These numbers were 13 and 10, respectively, in the standard-care group. 
Questionnaire response rates were slightly higher in the point-of-care group: 75% at 30 days and 
69% at 90 days, as opposed to 71% and 66%, respectively, for the standard-care group.
FIGURE 2  CONSORT chart showing flow of patients after recruitment.
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Research nurses checked whether patients had been appropriately recruited and the results are 
shown in Table 6. In addition to the six patients who were randomised in error and not followed 
up (reported above), a total of 23 patients (1%) were inappropriately recruited: 12 in the point-
of-care group and 11 in the standard-care group. These cases were followed up and analysed as 
planned on an intention-to-treat basis.
Protocol violations
Some 140 patients (12.4%) in the point-of-care group did not receive testing as recommended 
in the protocol, i.e. two panels consisting of CK-MB (mass), myoglobin and troponin (or one 
panel if the first troponin was positive). Of these, 34 did not receive any point-of-care testing at 
all, typically because of machine failure or inability to use the machine, while the remainder had 
fewer tests than recommended in the protocol. Two patients (0.2%) in the standard-care group 
received point-of-care testing.
Baseline characteristics, emergency department findings and 
diagnosis
Table 7 shows the characteristics and demographics of the recruited patients. The characteristics 
were as anticipated, with a mean age of 54.5 years, more men than women, and 12% with a past 
history of CHD.
Table 8 shows the presenting characteristics of the patients. The median duration between the 
onset of worst pain and arrival at hospital was just over 2 hours, excluding the 1% who suffered 
their worst pain after hospital arrival. There were no marked differences between the study 
groups in the nature or duration of pain, or the associated features.
TABLE 5  Analysis sets and study completion (all randomised patients)
PoC (n = 1132) SC (n = 1131) Total (n = 2263)
Analysis population [n (%)]
Full analysis set 1125 (99) 1118 (99) 2243 (99)
Failed to complete initial follow-up [n (%)]
No adequate consent obtained 4 (< 1) 8 (1) 12 (1)
Withdrew consent before 4 hours 0 2 (< 1) 2 (< 1)
Recruited in error and not followed up 3 (< 1) 3 (< 1) 6 (< 1)
Failed to complete 3-month follow-upa 18 (2) 10 (1) 28 (1)
Incomplete questionnaire datab [n (%)]
No EQ-5D questionnaire at 1 month 284 (25.2) 324 (29.0) 608 (27.1)
No EQ-5D questionnaire at 3 months 351 (31.2) 381 (34.1) 732 (32.6)
No resource use questionnaire at 1 month 285 (25.3) 324 (29.0) 609 (27.2)
No resource use questionnaire at 3 months 348 (30.9) 381 (34.1) 729 (32.5)
No patient resource use questionnaires 284 (25.2) 322 (28.8) 606 (27.0)
PoC, point of care; SC, standard care.
a  No details recorded for at least one major adverse event.
b  Denominator is patients in the full analysis set.22 Results
TABLE 6  Inappropriate recruitment
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Number inappropriately randomised [n (%)] 12 (1) 11 (1) 23 (1)
Reason [n (%)]
Diagnostic ECG changes 2 (< 1) 0 2 (< 1)
Known CHD with prolonged/recurrent episodes 3 (< 1) 5 (< 1) 8 (< 1)
Proven/suspected serious non-coronary pathology 1 (< 1) 1 (< 1) 2 (< 1)
Comorbidity or social problems requiring admission 0 1 (< 1) 1 (< 1)
Obvious non-cardiac 2 (< 1) 1 (< 1) 3 (< 1)
Presented > 12 hours after most significant pain 1 (< 1) 2 (< 1) 3 (< 1)
Other 3 (< 1) 1 (< 1) 4 (< 1)
PoC, point of care; SC, standard care.
TABLE 7  Patient demographics and characteristics
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Age (years)
n 1125 1118 2243
Mean (SD) 54.5 (13.8) 54.6 (14.4) 54.5 (14.1)
Median (IQR) 53.4 (44–64) 53.1 (44–64) 53.2 (44–64)
Minimum, maximum 22, 93 23, 96 22, 96
Gender [n (%)]
Male 683 (61) 624 (56) 1307 (58)
Female 442 (39) 494 (44) 936 (42)
Centre [n (%)]
Barnsley 162 (14) 164 (15) 326 (15)
Derriford 164 (15) 164 (15) 328 (15)
Edinburgh  228 (20) 224 (20) 452 (20)
Frenchay 233 (21) 231 (21) 464 (21)
Leeds 173 (15) 171 (15) 344 (15)
Leicester  165 (15) 164 (15) 329 (15)
Past history of CHD [n (%)]
n 1117 1110 2227
No  985 (88) 973 (88) 1958 (88)
Yes 132 (12) 137 (12) 269 (12)
Previous MI 60 (5) 65 (6) 125 (6)
Angina with positive diagnostic test  46 (4) 53 (5) 99 (4)
Previous CABG 12 (1) 15 (1) 27 (1)
Previous angioplasty 37 (3) 34 (3) 71 (3)
Stenosis > 50% on angiography 14 (1) 12 (1) 26 (1)
Unproven clinical label of CHD 36 (3) 31 (3) 67 (3)
Other 12 (1) 10 (1) 22 (1)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Risk factors [n (%)]
Diabetes 86 (8) 92 (8) 178 (8)
Hypertension 376 (34) 361 (33) 737 (33)
Hyperlipidaemia 271 (26) 282 (27) 553 (27)
Present smoker 310 (28) 316 (29) 626 (28)
Ex-smoker – last 10 years 144 (13) 129 (12) 273 (13)
Cocaine abuse 6 (1) 10 (1) 16 (1)
First-degree relative with angina/MI, onset age < 60 years 344 (33) 352 (34) 696 (33)
Use of aspirin in previous 7 days 207 (19) 215 (20) 422 (19)
> One episode rest angina in < 24 hours 75 (7) 74 (7) 149 (7)
Source of referral [n (%)]
n 1123 1115 2238
Referred by GP 188 (17) 189 (17) 377 (17)
Called emergency ambulance 481 (43) 510 (46) 991 (44)
Self-referred 419 (37) 375 (34) 794 (35)
Other 35 (3) 41 (4) 76 (3)
IQR, interquartile range; PoC, point of care; SC, standard care.
TABLE 7  Patient demographics and characteristics (continued)
TABLE 8  Pain at presentation
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Worst pain onset [n (%)]
n 1115 1103 2218
Before attendance 1102 (99) 1090 (99) 2192 (99)
After attendance 13 (1) 13 (1) 26 (1)
Duration between onset of worst pain and arrival at hospital (minutes)a
n 1102 1090 2192
Mean (SD) 241.3 (503.9) 218.9 (325.1) 230.2 (424.6)
Median (IQR) 129.5 (79–240) 128.5 (80–256) 129.0 (80–246)
Duration of longest episode of worst pain (minutes)
n 1083 1062 2145
Mean (SD) 97.1 (133.3) 98.7 (127.2) 97.9 (130.3)
Median (IQR) 60.0 (20–120) 50.0 (20–120) 50.0 (20–120)
Type of pain [n (%)]
n 1098 1081 2179
Continuous 815 (74) 848 (78) 1663 (76)
Intermittent 283 (26) 233 (22) 516 (24)
n 1034 1018 2052
Single episode 672 (65) 695 (68) 1367 (67)
Multiple episodes 362 (35) 323 (32) 685 (33)
continued24 Results
Table 9 shows the initial ECG and examination findings. A small proportion of patients had 
ST-segment deviations or T-wave inversions, although these were not deemed to be characteristic 
of myocardial ischaemia by the research nurse or recruiting doctor.
Table 10 shows the events in the ED, working diagnosis after initial assessment, the next-day ECG 
findings and final diagnosis. The proportions in each category differed between the final and 
initial diagnosis in both groups. More patients had a non-specific or other final diagnosis, and 
fewer had a final diagnosis of angina or ACS.
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Main chest pain [n (%)]
n 1114 1099 2213
Indigestion/burning (n, %) 81 (7) 73 (7) 154 (7)
Stabbing/sharp (n, %) 219 (20) 240 (22) 459 (21)
Aching/dull (n, %) 273 (25) 294 (27) 567 (26)
Gripping/crushing/heavy (n, %) 416 (37) 378 (34) 794 (36)
Non-specific/other (n, %) 125 (11) 114 (10) 239 (11)
Main site [n (%)]
n 1124 1114 2238
Central (n, %) 743 (66) 721 (65) 1464 (65)
Left chest (n, %) 285 (25) 288 (26) 573 (26)
Right chest (n, %) 24 (2) 26 (2) 50 (2)
Upper abdomen/epigastrium (n, %) 47 (4) 49 (4) 96 (4)
Other (n, %) 25 (2) 30 (3) 55 (2)
Radiationb [n (%)]
None  481 (43) 466 (42) 947 (43)
Left arm 365 (33) 384 (35) 749 (34)
Right arm 97 (9) 99 (9) 196 (9)
Neck 141 (13) 150 (14) 291 (13)
Jaw 71 (6) 97 (9) 168 (8)
Back 179 (16) 159 (14) 338 (15)
Other 97 (9) 90 (8) 187 (8)
Associated featuresb [n (%)]
Nausea 362 (33) 374 (34) 736 (34)
Vomiting 62 (6) 67 (6) 129 (6)
Dyspnoea 492 (45) 487 (44) 979 (45)
Sweating 503 (46) 470 (43) 973 (44)
Dyspepsia 83 (8) 67 (6) 150 (7)
Other 161 (15) 181 (17) 342 (16)
PoC, point of care; SC, standard care.
a  Patients with worst pain prior to arrival.
b  All that apply.
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Blood testing
Table 11 shows the number and proportion of the point-of-care group who received each test, the 
number and proportion with a positive test, and the mean (median) time from worst symptoms 
to sampling. Most positive cases arose from the first troponin sample, although about one-
quarter arose from the second sample.
Table 12 shows the number and proportion of patients in each study group receiving each 
laboratory blood test. Although most patients in the point-of-care group had negative point-of-
care tests, a substantial proportion went on to have laboratory testing with troponin I or T. In the 
standard-care group around 90% received laboratory testing with troponin I or T. Other cardiac 
biomarkers were rarely used.
TABLE 9  Examinations in ED
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
First ECG in ED [n (%)]
Normal 765 (68) 779 (70) 1544 (69)
T-wave inversion 79 (7) 74 (7) 153 (7)
ST depression 17 (2) 18 (2) 35 (2)
ST elevation 8 (1) 8 (1) 16 (1)
Bundle branch block 24 (2) 30 (3) 54 (2)
Other 205 (18) 179 (16) 384 (17)
Unknown/missing 27 (2) 30 (3) 55 (2)
Pulse (bpm)a
n 1120 1118 2238
Mean (SD) 76.6 (15.2) 76.2 (15.0) 76.4 (15.1)
Median (IQR) 75.0 (66–85) 75.0 (65–86) 75.0 (65–85)
Diastolic blood pressure (mmHg)
n 1117 1116 2233
Mean (SD) 80.3 (14.0) 80.1 (14.7) 80.2 (14.3)
Median (IQR) 80.0 (71–90) 80.0 (70–90) 80.0 (71–90)
Systolic blood pressure (mmHg)
n 1117 1117 2234
Mean (SD) 140.0 (22.9) 140.8 (22.5) 140.4 (22.7)
Median (IQR) 138.0 (124–154) 138.0 (125–155) 138.0 (125–154)
Killip class [n (%)]
Class I 1020 (91) 1020 (91) 2040 (91)
Class II 8 (1) 5 (< 1) 13 (1)
Class III 0 0 0
Class IV 1 (< 1) 0 1 (< 1)
Missing 96 (9) 93 (8) 189 (8)
bpm, beats per minute; PoC, point of care; SC, standard care.
a  First reading taken in ED.26 Results
Primary efficacy
Table 13 shows the results for the primary outcome, i.e. successful discharge home. This was 
defined as having left the hospital or as a decision to discharge made 4 hours after initial 
presentation, and no adverse event over the following 3 months. Some 509 patients were defined 
as discharged at initial presentation: 453 had left the hospital by 4 hours and 56 had a decision to 
discharge. However, five of these patients had a major adverse event over the following 3 months, 
so 504 were defined as being successfully discharged home.
TABLE 10  Events in ED and clinical diagnoses
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Events in EDa [n (%)]
Cardiac arrhythmia 8 (1) 8 (1) 16 (1)
Further pain requiring treatment 106 (11) 101 (10) 207 (11)
New ECG changes 8 (1) 21 (2) 29 (1)
Other symptoms requiring admission 26 (3) 20 (2) 46 (2)
Other events 35 (4) 26 (3) 61 (3)
Working diagnosis after initial assessment [n (%)]
Non-specific 233 (21) 219 (20) 452 (20)
Anxiety 51 (5) 49 (4) 100 (4)
Angina no ACS 173 (15) 178 (16) 351 (16)
ACS 334 (30) 332 (30) 666 (30)
Gastro-oesophageal 117 (10) 115 (10) 232 (10)
Musculoskeletal 108 (10) 102 (9) 210 (9)
Other 86 (8) 93 (8) 179 (8)
Unknown/missing 23 (2) 30 (3) 53 (2)
Next-day ECG [n (%)]
Normal 162 (14) 199 (18) 361 (16)
T-wave inversion 31 (3) 23 (2) 54 (2)
ST depression 1 (< 1) 2 (< 1) 3 (< 1)
ST elevation 5 (< 1) 3 (< 1) 8 (< 1)
Bundle branch block 6 (1) 8 (1) 14 (1)
Other abnormality 46 (4) 65 (6) 111 (5)
Not applicable 633 (56) 432 (39) 1065 (47)
Unknown/missing 35 (3) 66 (6) 101 (5)
Final diagnosis [n (%)]
Non-specific 366 (33) 336 (30) 702 (31)
Anxiety 36 (3) 23 (2) 59 (3)
Angina no ACS 89 (8) 63 (6) 152 (7)
ACS 87 (8) 72 (6) 159 (7)
Gastro-oesophageal 126 (11) 136 (12) 262 (12)
Musculoskeletal 143 (13) 169 (15) 312 (14)
Other 215 (19) 252 (23) 467 (21)
Unknown/missing 63 (6) 67 (6) 130 (6)
PoC, point of care; SC, standard care.
a  All that apply.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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The primary efficacy analyses were adjusted, as planned, for hospital, age, gender and known 
CHD. Patients in the point-of-care group were significantly more likely to be successfully 
discharged home (OR = 3.81, 95% CI 3.01 to 4.82, p < 0.001).
Variation between sites
Table 14 shows the results for each individual hospital. Full details are supplied in Appendix 3. 
There was marked variation in the primary outcome across the six hospitals. Point-of-care panel 
TABLE 11  Use and results of point-of-care tests
Sample 1 Sample 2
n (%) with troponin result 1076 (95.6) 842 (74.8)
n (%) with troponin > 0.02 µg/l 272 (25.5) 150 (17.8)
n (%) with troponin > 0.07 µg/l 113 (10.5) 28 (3.3)
n (%) with myoglobin result 1078 (95.6) 840 (74.7)
n (%) with myoglobin gradient > 25% – 67 (6.2)
n (%) with CK-MB (mass) result 1076 (95.6) 841 (74.8)
n (%) with both CK-MB (mass) result > 5 µg/l – 17 (2.0)
n (%) with CK-MB (mass) gradient > 1.6 µg/l – 2 (0.2)
Mean (median) time from worst symptoms to test (hours) 6.6 (4.1) 7.6 (5.7)
TABLE 12  Use of laboratory blood tests
PoC SC
n (%) with at least one laboratory troponin (I or T) 661 (58.8) 992 (88.7)
n (%) with at least one laboratory CK 177 (15.7) 155 (13.9)
n (%) with at least one laboratory CK-MB (mass) 1 (< 1) 1 (< 1)
n (%) with at least one LDH 1 (< 1) 0
n (%) with at least one laboratory myoglobin 9 (< 1) 9 (< 1)
LDH, laboratory lactate dehydrogenase; PoC, point of care; SC, standard care.
TABLE 13  Successful discharge home (primary outcome)
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 358 (32) 146 (13) 504 (22)
Not successfully discharged 767 (68) 972 (87) 1739 (78)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to 
discharge
763 (68) 971 (87) 1734 (77)
Initially discharged but re-attended with major adverse event 4 (< 1) 1 (< 1) 5 (< 1)
Discharge success by initial status
Initially discharged 362 (32) 147 (13) 509 (23)
Not in hospital at 4 hours 319 (28) 134 (12) 453 (20)
In hospital at 4 hours; decision made to discharge 43 (4) 13 (1) 56 (2)
PoC, point of care; SC, standard care.28 Results
assessment was associated with substantial increases in successful discharge rates at Barnsley and 
Edinburgh, modest increases at Derriford and Frenchay, and no increase at Leeds or Leicester.
Figure 3 shows how the proportion of patients in hospital varies with time from arrival and 
Figure 4 shows this for each individual hospital. Overall, point-of-care panel assessment is 
associated with fewer patients being in hospital between 4 and 24 hours after arrival. However, 
there was again variation between the hospitals. Point-of-care panel assessment was associated 
with markedly fewer patients being in hospital up to 24 hours at Barnsley and Edinburgh. At 
Derriford the difference in proportion in hospital was apparent only between 4 and 8 hours. At 
Frenchay the difference was marked up to 12 hours, but after 12 hours the proportion of patients 
in hospital was greater in the point-of-care group. At Leeds the difference between the groups 
did not emerge until 6 hours after attendance, but between 6 and 24 hours point-of-care panel 
assessment was associated with markedly fewer patients being in hospital. Finally, at Leicester 
there was no difference in the proportions in hospital up to 12 hours and only slightly fewer 
patients in hospital in the point-of-care group from 12 to 36 hours.
These differences probably reflect differences in standard care practice or the facilities for 
patients with chest pain at the hospitals. Standard care at Derriford was based on a troponin level 
measured 6 hours after arrival in hospital. This explains why the effect of point-of-care panel 
assessment at Derriford was limited to the 4- to 8-hour window. At Leeds all patients with chest 
pain are admitted to a clinical decision unit where diagnosis and management are undertaken 
without the pressure of the 4-hour target. This probably explains why the effect of point-of-care 
panel assessment was delayed at Leeds until 6 hours after arrival. At Leicester the point-of-care 
tests did not seem to alter decision-making with regards to hospital admission.
Per-protocol analysis
Table 15 shows the results of per-protocol analysis, with the 140 point-of-care patients who did 
not receive testing according to the protocol and the two standard-care patients who received 
point-of-care testing excluded. Exclusion of these patients does not markedly change the 
proportions in each group who are successfully discharged.
Variation over time
We analysed the primary outcome by each quarter-year to determine if the proportion 
successfully discharged varied over time due to clinical staff becoming more familiar with 
the intervention or changing management in the standard-care group. We also analysed the 
proportion of patients in the point-of-care group who did not receive testing according to 
TABLE 14  Primary outcome by study centre
PoC [n (%)] SC [n (%)] ORa (95% CI) RDb (95% CI) p-value
Overall 358/1125 (32) 146/1118 (13) 3.81 (3.01 to 4.82) 18.7 (15.4 to 22.1) < 0.001
Barnsley 110/162 (68) 43/164 (26) 6.97 (4.18 to 11.63) 41.3 (31.4 to 51.1) < 0.001
Derriford 43/164 (26) 21/164 (13) 2.48 (1.37 to 4.49) 13.4 (5.0 to 21.9) 0.003
Edinburgh 104/228 (46) 16/224 (7) 11.07 (6.23 to 19.66) 38.4 (31.1 to 45.6) < 0.001
Frenchay 50/233 (21) 9/231 (4) 7.03 (3.35 to 14.75) 17.4 (11.6 to 23.2) < 0.001
Leeds 1/173 (1) 8/171 (5) 0.12 (0.01 to 1.03) –4.0 (–7.2 to –0.7) 0.054
Leicester 50/165 (30) 49/164 (30) 1.11 (0.66 to 1.84) 0.4 (–9.5 to 10.3) 0.699
PoC, point of care; RD, risk difference; SC, standard care.
a  Adjusted for age, gender and known CHD. Overall result is also adjusted for centre. The p-value corresponds to adjusted OR.
b  Absolute risk difference.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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the recommended protocol to determine whether increased familiarity over time led to fewer 
protocol deviations. The results are outlined in Table 16. The proportion successfully discharged 
in the point-of-care group appears to dip in the middle of the trial and then rise again at the 
end, whereas the proportion successfully discharged in the standard-care group appears to 
progressively fall throughout the trial. The proportion of patients in the point-of-care group who 
did not receive testing according to the recommended protocol remained relatively constant.
We compared the primary efficacy analysis before and after the amendment to the troponin 
threshold in the point-of-care protocol. Before the amendment the proportion successfully 
discharged in the point-of-care group was 210/729 (29%) compared with 107/721 (15%) in 
the standard-care group (adjusted OR = 2.79, 95% CI 2.09 to 3.72). After the amendment the 
proportion successfully discharged in the point-of-care group was 148/396 (37%) compared with 
39/397 (10%) in the standard-care group (adjusted OR = 5.61, 95% CI 3.79 to 8.31, p < 0.001). 
Hence, it appeared that the effect of point-of-care panel assessment increased after amendment of 
FIGURE 3  Duration from arrival to discharge from hospital (all centres).
FIGURE 4  Duration from arrival to discharge from hospital (individual centres).
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the protocol, although some of this may be attributable to a lower successful discharge rate in the 
standard-care group.
Secondary efficacy
Length and location of hospital stay
The mean length of the initial hospital stay was 29.6 hours in the point-of-care group and 
31.8 hours in the standard-care group [mean difference = 2.1 hours, 95% CI –3.7 to 8.0 hours, 
p = 0.462 (t-test)]. The median length of initial hospital stay was markedly shorter for both 
groups, reflecting the positively skewed nature of length-of-stay data: 8.8 hours for the point-of-
care group and 14.2 hours for the standard-care group (p < 0.001, equality-of-medians test). The 
two groups had significantly different distributions of length of stay (p < 0.001, Mann–Whitney 
U-test). Point-of-care panel assessment was therefore associated with reduced probability of 
hospital admission and shorter median length of stay, but there was no significant difference in 
mean length of stay.
TABLE 15  Primary outcome: per-protocol analysis
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 326 (33) 145 (13) 471 (22)
Not successfully discharged 659 (67) 971 (87) 1630 (78)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been 
made to discharge
655 (66) 970 (87) 1625 (77)
Initially discharged but re-attended with major adverse event 4 (< 1) 1 (< 1) 5 (< 1)
Discharge success by initial status
Initially discharged 330 (34) 146 (13) 476 (23)
Not in hospital at 4 hours 292 (30) 133 (12) 425 (20)
In hospital at 4 hours, decision made to discharge 38 (4) 13 (1) 51 (2)
PoC, point of care; SC, standard care.
TABLE 16  Primary outcome and point-of-care protocol deviations: by quarter
Quarter PoC protocol deviations [n (%)]
PoC successfully 
discharged [n (%)]
SC successfully 
discharged [n (%)]
January to March 2008 3/34 (9) 13/34 (38) 10/33 (30)
April to June 2008 41/286 (14) 93/286 (33) 42/286 (15)
July to September 2008 33/199 (17) 57/199 (29) 30/195 (15)
October to December 2008 24/239 (10) 64/239 (27) 27/235 (11)
January to March 2009 22/195 (10) 77/195 (35) 24/222 (11)
April to June 2009 17/150 (11) 54/150 (36) 13/147 (9)
PoC, point of care; SC, standard care.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Table 17 shows the total number of days spent in hospital over the 3-month follow-up and the 
number of days spent in coronary care or intensive care, including the initial hospital admission. 
We did not record fractions of days spent in hospital for this analysis and recorded an inpatient 
day only if the patient stayed overnight. Hence, a proportion of patients were recorded as having 
no inpatient days if their initial hospital visit did not result in an overnight stay and they were not 
admitted on a subsequent occasion. More patients in the point-of-care group had no inpatient 
days recorded during follow-up (54% vs 40%, p< 0.001). This reflected the difference in the 
proportion of patients in Figure 5 who were no longer in hospital 12 hours after attendance, as 
patients who are discharged before 12 hours and are not re-admitted are likely to be recorded as 
having no inpatient days over follow-up.
Despite this difference in the proportion with no inpatient days, there was no difference in the 
mean days per patient or the total inpatient days in the two groups. Figure 5 compares histograms 
for total days spent in hospital in the two groups to show why this was. The difference between 
the two groups in the proportions of patients having no inpatient stay was reflected in the 
difference in proportions having one inpatient day. So point-of-care panel assessment saved one 
inpatient day in about 14%. However, a few patients in both groups had a very high number of 
inpatient days (over 30). There were a few more of these in the point-of-care group, and enough 
to contribute disproportionately to the mean and total inpatient days for the group. Hence, point-
of-care panel assessment reduced the proportion of patients completely avoiding admission but 
did not reduce overall inpatient days. Point-of-care panel assessment was also associated with a 
higher use of coronary care over follow-up (4% vs 3%, p = 0.041), although only a small minority 
of patients received any coronary care or intensive care.
TABLE 17  Inpatient care at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Percentage 
difference 
(95% CI) p-value
Days in hospital at any location
n (%) with at least one day 518 (46.0) 670 (59.9) 1188 (53.0) –13.9 (–18.0 to 
–9.8)
< 0.001
Mean days per patient 1.8 1.7 1.7 0.815
Total days (all patients) 1961 1908 3869
Days in coronary care
n (%) with at least one day 50 (4.4) 31 (2.8) 81 (3.6) 1.7 (0.1 to 3.2) 0.041
Mean days per patient 0.17 0.09 0.13 0.033
Total days (all patients) 190 105 295
Days in intensive care
n (%) with at least one day 8 (< 1) 3 (< 1) 11 (< 1) 0.4 (–0.2 to 1.0) 0.225
Mean days per patient 0.08 0.01 0.04 0.259
Total days (all patients) 76 14 90
PoC, point of care; SC, standard care.32 Results
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Initial care in the first 24 hours
Table 18 shows the proportion of patients in each group receiving various elements of care in the 
first 24 hours after arrival. Only a small proportion in each group was admitted from the ED on 
to coronary care, but twice as many were admitted to coronary care in the point-of-care group 
(4% vs 2%, p = 0.001). There were no significant differences between point-of-care and standard 
care in the proportions receiving glyceryl trinitrate (GTN), heparin, glycoprotein inhibitors, 
antacids or beta-blockers. More patients in the point-of-care group received clopidogrel 
(21% vs 16%, p = 0.002), while more patients in the standard-care group received aspirin (60% vs 
55%, p = 0.031). There were non-significant trends towards greater use of angiography and PCI in 
the point-of-care group and greater use of analgesia in the standard-care group.
Interventions, re-attendances, re-admissions, investigations and outpatient 
reviews up to 3 months
Table 19 shows the proportion of patients receiving cardiac interventions in each study group 
over the 3-month follow-up period, including during the initial hospital admission. Very few 
patients received cardiac interventions and there were no significant differences between the 
study groups.
Table 20 shows the proportion of patients in each group with any ED attendance, the proportion 
with a potentially chest pain-related attendance, the proportion with any subsequent hospital 
admission (i.e. any admission other than that arising from their initial visit) and the proportion 
with a potentially chest pain-related hospital admission over the follow-up 3 months. There were 
no significant differences between the two groups in any of these outcomes.
Table 21 shows the proportion of patients in each group receiving each investigation over the 
3-month follow-up. Most patients did not receive any of these investigations. There were no 
differences between the two groups in the proportions receiving any of the investigations.
Table 22 shows the proportion of patients in each group who received outpatient follow-up (any 
or potentially chest pain related). Patients in the point-of-care group were slightly more likely to 
have a chest pain-related outpatient review (21% vs 18%, p = 0.05).
TABLE 18  Initial care in the first 24 hours
PoC (n = 1125) [n (%)] SC (n = 1118) [n (%)] Total (n = 2243) [n (%)] p-value
Admitted to coronary care 50 (4) 21 (2) 71 (3) 0.001
Received GTN 446 (40) 460 (42) 906 (41) 0.327
Received heparin 206 (18) 186 (17) 392 (18) 0.381
Received glycoprotein inhibitors 8 (1) 7 (1) 15 (1) 0.822
Received antacid 90 (8) 108 (10) 198 (9) 0.128
Received angiography 16 (1) 8 (1) 24 (1) 0.105
Received aspirin 618 (55) 663 (60) 1281 (58) 0.031
Received beta-blocker 108 (10) 105 (10) 213 (10) 0.967
Received clopidogrel 237 (21) 176 (16) 413 (19) 0.002
Received analgesic 373 (34) 407 (37) 780 (36) 0.058
Received any other drugs 316 (29) 340 (31) 656 (30) 0.150
Received angioplasty/stent 11 (1) 4 (< 1) 15 (1) 0.073
PoC, point of care; SC, standard care.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Patient-reported use of health services
Tables 23 and 24 show the number and proportion of patients in each group who reported having 
used various health services over the previous month in their 1- and 3-month resource use 
questionnaires. The only significant difference was in the proportion admitted to hospital. There 
may have been some confusion in responses to this question, with some patients reporting the 
initial hospital admission while others reported only subsequent admissions.
TABLE 19  Cardiac interventions at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
n (%) needing thrombolysis 1 (< 1) 2 (< 1) 3 (< 1) 0.624
n (%) needing PCI 29 (3) 29 (3) 58 (3) 1.000
n (%) needing emergency PCI 7 (1) 12 (1) 19 (1) 0.260
n (%) needing CABG 11 (1) 5 (< 1) 16 (1) 0.209
PoC, point of care; SC, standard care.
TABLE 20  Re-attendances at ED and hospital at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
n (%) of ED attendances 140 (12) 138 (12) 278 (12) 0.949
n (%) of chest pain-related ED attendances 107 (10) 103 (9) 210 (9) 0.828
n (%) of subsequent hospital admissions 117 (10) 122 (11) 239 (11) 0.732
n (%) of subsequent chest pain-related 
admissions
84 (7) 99 (9) 183 (8) 0.247
PoC, point of care; SC, standard care.
TABLE 21  Investigations at 3 months
PoC (n = 1125) [n (%)] SC (n = 1118) [n (%)] p-value
Exercise treadmill test 231 (20.5) 226 (20.2) 0.893
Echocardiography 73 (6.5) 60 (5.4) 0.300
Radionuclide scan  36 (3.2) 33 (3.0) 0.827
24-hour tape 12 (1.1) 19 (1.7) 0.270
Coronary angiography 81 (7.2) 78 (7.0) 0.901
Abdominal ultrasound 13 (1.2) 20 (1.8) 0.284
Upper gastrointestinal endoscopy 9 (0.8) 17 (1.5) 0.162
Other test 20 (1.8) 17 (1.5) 0.755
PoC, point of care; SC, standard care.
TABLE 22  Attendances as outpatients at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
n (%) with any outpatient attendance 334 (30) 322 (29) 656 (29) 0.676
n (%) with a chest pain-related outpatient attendance 241 (21) 202 (18) 443 (20) 0.050
PoC, point of care; SC, standard care.36 Results
Patient-reported time taken off work
Tables 25 and 26 show the number and proportion of patients in each group who reported at 
1 and 3 months that they had taken time off work during the last month, had not taken time 
off, were retired and were not in paid employment. They also show the median (IQR) number 
of days taken off. Around one-half of those in paid employment had taken time off during the 
TABLE 23  Patient-reported health service use at 1 month
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
Questionnaires returned [n (%)] 841 (74.8) 795 (71.1) 1636 (72.9)
n (%) using telephone health advice 232/760 (31) 221/711 (31) 453/1471 (31) 0.821
n (%) using GP surgery consultations 555/799 (69) 537/758 (71) 1092/1557 (70) 0.580
n (%) using GP home visits 45/749 (6) 43/702 (6) 88/1451 (6) 1.000
n (%) using nurse home visits 44/756 (6) 46/698 (7) 90/1454 (6) 0.587
n (%) using social worker visits 14/751 (2) 18/698 (3) 32/1449 (2) 0.376
n (%) attending ED 282/765 (37) 280/728 (38) 562/1493 (38) 0.557
n (%) attending outpatients 334/778 (43) 277/726 (38) 611/1504 (41) 0.066
n (%) using other health services 83/733 (11) 76/660 (12) 159/1393 (11) 0.933
n (%) admitted to hospital 182/832 (22) 208/786 (26) 390/1618 (24) 0.032
n (%) operated on 33/829 (4) 32/784 (4) 65/1613 (4) 1.000
n (%) having ECG 224/813 (28) 228/765 (30) 452/1578 (29) 0.344
n (%) having exercise stress test  184/818 (22) 157/769 (20) 341/1587 (21) 0.328
n (%) having heart monitor  43/806 (5) 58/757 (8) 101/1563 (6) 0.064
n (%) having abdominal ultrasound 59/806 (7) 54/746 (7) 113/1552 (7) 1.000
n (%) having coronary angiography 91/813 (11) 79/756 (10) 170/1569 (11) 0.685
PoC, point of care; SC, standard care.
TABLE 24  Patient-reported health service use at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
Questionnaires returned [n (%)] 787 (70.0) 745 (66.6) 1532 (68.3)
n (%) using telephone health advice 151/661 (23) 145/633 (23) 296/1294 (23) 1.000
n (%) using GP surgery consultations 512/746 (69) 457/701 (65) 969/1447 (67) 0.180
n (%) using GP home visits 27/646 (4) 40/626 (6) 67/1272 (5) 0.080
n (%) using nurse home visits 32/645 (5) 39/622 (6) 71/1267 (6) 0.330
n (%) using social worker visits 12/642 (2) 21/621 (3) 33/1263 (3) 0.112
n (%) attending ED 106/659 (16) 112/635 (18) 218/1294 (17) 0.459
n (%) attending outpatients 281/693 (41) 265/661 (40) 546/1354 (40) 0.868
n (%) using other health services 84/625 (13) 80/598 (13) 164/1223 (13) 1.000
n (%) admitted to hospitals 76/779 (10) 79/742 (11) 155/1521 (10) 0.611
n (%) operated on 27/772 (3) 21/734 (3) 48/1506 (3) 0.558
n (%) having ECG 97/762 (13) 74/720 (10) 171/1482 (12) 0.144
n (%) having exercise stress test  83/761 (11) 71/724 (10) 154/1485 (10) 0.497
n (%) having heart monitor  32/760 (4) 28/712 (4) 60/1472 (4) 0.794
n (%) having abdominal ultrasound 45/758 (6) 42/716 (6) 87/1474 (6) 1.000
n (%) having coronary angiography 39/755 (5) 31/717 (4) 70/1472 (5) 0.465
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first month and around one-third had taken time off during the third month. There were no 
differences in time taken off work between the two groups.
Health utility
Table 27 compares mean EQ-5D scores at 1 and 3 months between the point-of-care and 
standard-care groups. There were no significant differences in mean EQ-5D scores at either 
time point.
Patient satisfaction
Table 28 shows the proportion of responses in each category for each question of the patient 
satisfaction questionnaire. Most patients were satisfied with most aspects of their care, with only 
a small proportion rating their care as poor. The exception was the question on advice about 
ways to avoid illness and stay healthy, where 19% rated their care as poor and only 14% rated it 
as excellent.
Patients receiving point-of-care panel assessment were generally more likely to rate their care as 
excellent or very good, while those receiving standard care were more likely to rate their care as 
good, fair or poor. However, this trend was clearly significant only on the final question of overall 
satisfaction with the service received, whilst being borderline significant for questions relating to 
the urgency of assessment, explanations given and personal interest shown in the patient and his 
or her medical problems.
Table 29 shows the characteristics of responders and non-responders in the two groups. At both 1 
and 3 months the responders were older and more likely to be female.
TABLE 25  Patient-reported time taken off work at 1 month
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
Questionnaires returned [n (%)] 841 (74.8) 795 (71.1) 1636 (72.9)
n (%) taken time off 226 (27) 215 (28) 441 (27) 0.841
n (%) not taken time off 227 (27) 222 (28) 449 (28)
n (%) retired 107 (13) 65 (8) 172 (11)
n (%) not in paid employment 267 (32) 279 (36) 546 (34)
Median (IQR) days off 8.0 (3–20) 10.0 (4–20) 10.0 (3–20) 0.29
PoC, point of care; SC, standard care.
TABLE 26  Patient-reported time taken off work at 3 months
PoC (n = 1125) SC (n = 1118) Total (n = 2243) p-value
Questionnaires returned [n (%)] 787 (70.0) 745 (66.6) 1532 (68.3)
n (%) taken time off 136 (17) 123 (17) 259 (17) 0.498
n (%) not taken time off 275 (35) 278 (38) 553 (37)
n (%) retired 89 (11) 61 (8) 150 (10)
n (%) not in paid employment 279 (36) 271 (37) 550 (36)
Median (IQR) of days off 11.0 (4–40) 9.0 (3–35) 10.0 (3–40) 0.399
PoC, point of care; SC, standard care.38 Results
TABLE 28  Patient satisfaction with care: how would you rate the following?
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
n (%) of questionnaires returned 841 (74.8) 796 (71.2) 1637 (73.0)
The urgency with which you were assessed
n 838 791 1629
Poor 10 (1) 16 (2) 26 (2)
Fair 40 (5) 51 (6) 91 (6)
Good 132 (16) 160 (20) 292 (18)
Very good 317 (38) 257 (32) 574 (35)
Excellent 339 (40) 307 (39) 646 (40)
p-value 0.038
The thoroughness of your assessment
n 837 791 1628
Poor 9 (1) 10 (1) 19 (1)
Fair 41 (5) 37 (5) 78 (5)
Good 140 (17) 162 (20) 302 (19)
Very good 325 (39) 295 (37) 620 (38)
Excellent 322 (38) 287 (36) 609 (37)
p-value 0.163
Explanations given to you about medical procedures and tests
n 837 789 1626
Poor 19 (2) 20 (3) 39 (2)
Fair 55 (7) 57 (7) 112 (7)
Good 167 (20) 177 (22) 344 (21)
Very good 315 (38) 301 (38) 616 (38)
Excellent 281 (34) 234 (30) 515 (32)
p-value 0.066
TABLE 27  EQ-5D health utility
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Difference between 
means (95% CI) p-value
1 month
n (%) of responses 825 (73.3) 770 (68.9) 1595 (71.1)
Mean (SD) 0.742 (0.289) 0.759 (0.267) 0.750 (0.279) –0.017 (–0.04 to 0.01) 0.614
Median (IQR) 0.796 (0.69–1.00) 0.796 (0.69–1.00) 0.796 (0.69–1.00)
3 months
n (%) of responses 756 (67.2) 717 (64.1) 1473 (65.7)
Mean (SD) 0.752 (0.291) 0.759 (0.279) 0.755 (0.285) –0.007 (–0.03 to 0.02) 0.638
Median (IQR) 0.796 (0.69–1.00) 0.796 (0.69–1.00) 0.796 (0.69–1.00)
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PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Attention given to what you have to say
n 837 792 1629
Poor 24 (3) 21 (3) 45 (3)
Fair 62 (7) 67 (8) 129 (8)
Good 207 (25) 193 (24) 400 (25)
Very good 346 (41) 317 (40) 663 (41)
Excellent 198 (24) 194 (24) 392 (24)
p-value 0.996
Advice you got about ways to avoid illness and stay healthy
n 831 776 1607
Poor 151 (18) 161 (21) 312 (19)
Fair 142 (17) 121 (16) 263 (16)
Good 210 (25) 192 (25) 402 (25)
Very good 209 (25) 197 (25) 406 (25)
Excellent 119 (14) 105 (14) 224 (14)
p-value 0.487
Friendliness and courtesy shown to you by hospital staff
n 839 790 1629
Poor 7 (1) 8 (1) 15 (1)
Fair 39 (5) 28 (4) 67 (4)
Good 121 (14) 141 (18) 262 (16)
Very good 307 (37) 272 (34) 579 (36)
Excellent 365 (44) 341 (43) 706 (43)
p-value 0.605
Personal interest in you and your medical problems
n 837 788 1625
Poor 24 (3) 26 (3) 50 (3)
Fair 77 (9) 89 (11) 166 (10)
Good 204 (24) 206 (26) 410 (25)
Very good 308 (37) 281 (36) 589 (36)
Excellent 224 (27) 186 (24) 410 (25)
p-value 0.044
Respect shown to you, and attention to your privacy
n 837 788 1625
Poor 20 (2) 21 (3) 41 (3)
Fair 65 (8) 67 (9) 132 (8)
Good 174 (21) 179 (23) 353 (22)
Very good 338 (40) 276 (35) 614 (38)
Excellent 240 (29) 245 (31) 485 (30)
p-value 0.870
continued
TABLE 28  Patient satisfaction with care: how would you rate the following? (continued)40 Results
Adverse events
Table 30 shows the number of major adverse events in each study group up to 3 months. The 
causes of death were MI (two cases), cancer (two cases), multiorgan failure, pneumonia and 
unknown (two cases). Adverse event rates were very low, with an overall death rate of 3.6 per 
thousand, non-fatal MI rate of 4.5 per thousand and emergency revascularisation rate of 10.7 per 
thousand. The analyses were adjusted as planned for age, gender and known CHD. There were no 
significant differences in adverse event rates between the two groups.
As shown in Table 13 (primary efficacy), five of the adverse events occurred in patients who were 
discharged after initial assessment. As these could potentially represent episodes of suboptimal 
care, these are described in Table 31.
The proportion of admitted patients ultimately diagnosed as having 
myocardial infarction
Overall 158/2243 (7%) patients were diagnosed as having AMI during their initial presentation: 
157 were diagnosed on the basis of a troponin rise and one developed ST elevation and received 
immediate reperfusion.
PoC (n = 1125) SC (n = 1118) Total (n = 2243)
Reassurance and support offered to you by hospital staff
n 836 787 1623
Poor 31 (4) 33 (4) 64 (4)
Fair 79 (9) 81 (10) 160 (10)
Good 207 (25) 182 (23) 389 (24)
Very good 288 (34) 275 (35) 563 (35)
Excellent 231 (28) 216 (27) 447 (28)
p-value 0.870
Amount of time the hospital staff gave you
n 839 789 1628
Poor 32 (4) 28 (4) 60 (4)
Fair 108 (13) 127 (16) 235 (14)
Good 246 (29) 230 (29) 476 (29)
Very good 278 (33) 247 (31) 525 (32)
Excellent 175 (21) 157 (20) 332 (20)
p-value 0.210
Overall, how satisfied are you with the service you received?
n 839 788 1627
Poor 20 (2) 22 (3) 42 (3)
Fair 51 (6) 68 (9) 119 (7)
Good 153 (18) 172 (22) 325 (20)
Very good 326 (39) 284 (36) 610 (37)
Excellent 289 (34) 242 (31) 531 (33)
p-value 0.008
PoC, point of care; SC, standard care.
TABLE 28  Patient satisfaction with care: how would you rate the following? (continued)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
41   Health Technology Assessment 2011; Vol. 15: No. 23 DOI: 10.3310/hta15230
The proportion diagnosed with AMI was slightly higher in the point-of-care group [82/1125 
(7.3%) vs 76/1118 (6.8%)] but this was not statistically significant (p = 0.650). 
The proportion of admitted patients diagnosed with AMI was 82/763 in the point-of-care group 
and 75/971 in the standard-care group (10.7% vs 7.7%, p = 0.029), suggesting that point-of-care 
panel assessment was associated with a higher proportion of admitted patients having AMI. 
This reflects a difference in the denominator between these two proportions, rather than the 
TABLE 29  Characteristics of responders and non-responders to EQ-5D questionnaire
PoC (n = 1125) SC (n = 1118)
Responders Non-responders Responders Non-responders
(n = 825) (n = 300) (n = 771) (n = 347)
1 month
Age (years) [mean (SD)] 56.7 (13.1) 48.5 (14.0) 57.1 (13.9) 48.9 (13.8)
Gender
Male [n (%)] 468 (56.7) 215 (71.7) 410 (53.2) 214 (61.7)
Female [n (%)] 357 (43.3) 85 (28.3) 361 (46.8) 133 (38.3)
Previous CHD
Yes [n (%)] 50 (6.1) 10 (3.4) 45 (5.9) 20 (5.8)
No [n (%)] 767 (93.9) 288 (96.6) 719 (94.1) 324 (94.9)
3 months
Age (years) [mean (SD)] 57.1 (13.3) 49.0 (13.2) 58.1 (13.7) 48.1 (13.3)
Gender
Male [n (%)] 439 (57.2) 244 (68.2) 386 (53.3) 238 (60.4)
Female [n (%)] 328 (42.8) 114 (31.8) 338 (46.7) 156 (39.6)
Previous CHD
Yes [n (%)] 49 (6.5) 11 (3.1) 43 (6.0) 22 (5.6)
No [n (%)] 710 (93.5) 345 (96.9) 675 (94.0) 368 (94.4)
PoC, point of care; SC, standard care.
TABLE 30  Major adverse events
PoC (n = 1125) 
[n (%)]
SC (n = 1118) 
[n (%)]
Total (n = 2243) 
[n (%)] OR (95% CI)a p-valuea
Any event 36 (3) 26 (2) 62 (3) 1.31 (0.78 to 2.20) 0.313
Death 6 (1) 2 (< 1) 8 (< 1) 3.4 (0.7 to 17.3) 0.142
Non-fatal AMI 5 (< 1) 5 (< 1) 10 (< 1) 0.9 (0.3 to 3.2) 0.903
Hospitalisation for ACS without AMI 18 (2) 9 (1) 27 (1) 1.8 (0.8 to 4.1) 0.149
Life-threatening arrhythmia 6 (1) 2 (< 1) 8 (< 1) 3.2 (0.6 to 15.9) 0.160
Emergency revascularisation 10 (1) 14 (1) 24 (1) 0.7 (0.3 to 1.5) 0.324
PoC, point of care; SC, standard care.
a  Adjusted for age, gender and known CHD.42 Results
numerator, i.e. point-of-care was associated with fewer admissions rather than more diagnosis 
of AMI.
Economic analysis
Tables 32 and 33 show the unit costs used in the main analysis and the microcosting, respectively.
Table 34 shows the unit costs used to estimate the cost per patient of providing point-of-care 
panel assessment. The total cost per patient of point-of-care panel assessment was estimated as 
the sum of a number of components: the cost of the machine and of periodic maintenance, the 
cost of calibration and quality control during testing, and the annual testing rate for the machine. 
Information was provided by Siemens Healthcare Diagnostics. Machine and maintenance costs 
were annualised to the index year (2009). The cost applied to the analyses reported here is that 
for an annual rate of 1500 full panels (£21.33 per panel). It is worth noting that the relationship 
between cost and annual rate of testing is known with certainty only for the rates reported 
in Table 34.
Data were collected from 246 patients for the microcosting study. The average age of this sample 
was 54 years, 52% were male (slightly lower than the overall percentage: 58% – Table 7) and 12% 
had a history of CHD. The results are shown in Table 35. The point-of-care panel assessment 
added £38.13 per patient managed in this arm of the trial. Staff costs were £11.55 higher in the 
point-of-care group, reflecting the increased level of staff involvement required to deliver the 
intervention. Overall, the microcosting study showed that point-of-care panel assessment added 
£53.16 to the costs of ED management.
Table 36 shows the number of patients in each group receiving other interventions during their 
initial assessment, the number of interventions received and the cost per patient of providing 
these interventions. The small differences noted in the use of aspirin and clopidogrel between 
the two groups did not produce a significant difference in the cost per patient of medications. 
The standard-care group received more laboratory blood tests, leading to an excess cost of £9.42 
per patient compared with the point-of-care group. The standard-care group also received more 
ECGs than the point-of-care group, although this resulted in only a small (£1.95) additional 
cost per patient. More patients in the point-of-care group received angiography or PCI, but the 
TABLE 31  Adverse events occurring in patients discharged after initial assessment
Age and 
gender Study group Testing at initial presentation Working diagnosis Adverse event
43, female Point of care PoC tests negative, taken 505 and 
600 minutes after worst pain
Musculoskeletal pain Hospitalisation for ACS 50 days later
63, male Point of care PoC tests negative, taken 721 and 
824 minutes after worst pain
Musculoskeletal pain Hospitalisation for ACS 1 day later
64, female Standard care Troponin negative 1606 minutes 
after worst pain
Angina, no ACS Non-fatal AMI 32 days later
78, female Point of care PoC tests negative, taken 800 and 
900 minutes after worst pain
Gastro-oesophageal 
pain
Died from metastatic pancreatic 
carcinoma 75 days later
78, male Point of care CK-MB and myoglobin negative, 
troponin 0.06 μg/l and 0.07 μg/l at 
909 and 1005 minutes after worst 
pain
Angina, no ACS Life-threatening arrhythmia 
(supraventricular tachycardia) 48 
days later
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TABLE 32  Unit costs used in the economic evaluation
Trial costs Cost (£)/event Sourcea
PoC panel assessment See Table 34
Cardiac interventions (adjusted for cost of mean length of stay – see below)
CABG 6806.86 HRG code Average of EA14Z–EA16Z 
PCI for stenting 2012.97 HRG code Average of EA31Z–EA32Z
Thrombolysis  780.00 BNF50 Alteplase: accelerated regimen, 15 mg IV injection + 50 mg IV 
infusion (30 minutes) + 35 mg IV infusion (1 hour)
Diagnostic procedures
Angiogram  129.96 HRG code Average of RA16Z–RA18Z – contrast fluoroscopy procedures
Radionuclide scan 221.32 HRG code Average of RA35Z–RA39Z – nuclear medicine
Exercise treadmill test 116.04 HRG code EA47Z – ECG monitoring and stress testing
ECG 116.04 HRG code EA47Z – ECG monitoring and stress testing
24-hour monitoring test 116.04 HRG code EA47Z – ECG monitoring and stress testing
Echocardiogram 176.39 HRG code EA46Z – simple echocardiogram
Transoesophageal echocardiogram 104.69 HRG code EA45Z – complex echocardiogram 
Abdominal ultrasound 57.42 HRG code AVERAGE of RA23Z–RA24Z, across both outpatient and 
admitted care
Upper gastrointestinal endoscopy 258.62 HRG code FZ03A – diagnostic and intermediate procedures on the 
upper gastrointestinal tract 19 years and over
MRI scan 198.53 HRG code Average of RA01Z–RA03Z
Outpatient clinic/centre visits
Cardiology – first attendance 160.08 HRG code 320 – cardiology clinic (assume consultant led)
Cardiology – follow-up visit 70.83 HRG code 320 – cardiology clinic (assume non-consultant led)
Cardiac surgery – first attendance 270.45 HRG code 172 – cardiac surgery (assume consultant led)
Cardiac surgery – follow-up attendance 272.85 HRG code 172 – cardiac surgery (assume non-consultant led)
Cardiothoracic surgery – first attendance 202.27 HRG code 170 – cardiothoracic surgery (assume consultant led)
Cardiothoracic surgery – follow-up 
attendance
215.03 HRG code 170 – cardiothoracic surgery (assume non-consultant led)
Cardiac rehabilitation  195 HRG code average of VB38Z – rehabilitation for AMI and other cardiac 
disorders (across levels 1 and 2)
Rapid-access chest pain clinic 569.78 £458 (from Goodacre et al.51) inflated according to Hospital & Community 
Health Services (pay and prices index)52
Hospital cost per day
Coronary care 1115.78 HRG code Average of XC01Z–XC07Z – adult critical care (cardiac ICU)
Intensive care 1410.54 HRG code Average of XC01Z–XC07Z – adult critical care (ITU)
Medical assessment unit 276.21 HRG code VEB10Z Actual or suspected MI – observation ward – inflated 
according to Hospital & Community Health Services (pay and 
prices index)52
Clinical ward 276.21 Assumed same as observation ward
Community health-care costs
GP – surgery (17.2 minutes’ contact) 52.00 8.8b GP52 (p. 109)
GP – home visit (23.4 minutes) 58.00 8.8b GP52 (p. 109)
Nurse – home visit (quarter hour) 21.65 8.4 nurse specialist (community)52
Social worker visit (1 hour) 28.46 9.2 social worker (adult)52
HRG, Healthcare Resource Group; ITU, Intensive Therapy Unit; IV, intravenous; MRI, magnetic resonance imaging; PoC, point of care.
a  Unless specified, source is National Schedule of Reference Costs 2007/08 – NHS Trusts.44 Results
TABLE 33  Unit costs used in costing ED staff costs for the initial episode
Resource Cost (£) Source52
Consultant 163 13.4 Consultant: medical (all duties/patient contact)
Trainee specialist doctor, year 4 52 13.3 Specialty doctor (40-hour week)
Trainee specialist doctor, year 3 51 13.3 Specialty doctor (40-hour week)
Trainee specialist doctor, year 2 49 13.3 Specialty doctor (40-hour week)
Trainee specialist doctor, year 1 47 13.3 Specialty doctor (40-hour week)
Staff grade 60 Staff grade (Table 3, p, 169)
Senior house officer 32 13.2 Foundation house officer 2 (56-hour week)
House officer 27 13.1 Foundation house officer 1 (56-hour week)
Nursing director (band 8/9) 85 Table 2, p, 168 (band 8b) (patient contact)
Nurse manager (band 7) 74 12.1 Nurse team manager (patient contact)
Nurse team leader (band 6) 65 12.2 Nurse team leader (patient contact)
Staff nurse (band 5) 47 12.3 Nurse, 24-hour ward/RN (patient contact)
Clinical/health-care assistant  23 12.5 Clinical support worker (patient contact)
RN, research nurse.
TABLE 34  Point-of-care testing unit costs
Cost component Cost (£)
Panel costs (includes reagent, machine and maintenance)
Based on 1500 full panelsa 20.54
Based on 3000 full panelsa 15.70
Based on 3000 troponin-only panelsa 5.70
Calibration and quality control for full panel (per annum)b 1426
Calibration and quality control for troponin only panel (per annum)b 1397
Total cost per panel
Based on 1500 full panels 21.33
Based on 3000 full panels 16.18
Based on 3000 troponin-only panels 6.17
a  Costs provided by Hilda Crockett, Marketing Manager Point of Care, Siemens Healthcare Diagnostics.
b  Based on 5-minute daily systems check, twice-weekly 15-minute quality control check and 5 minutes per reagent calibration check every 60 
days, and Agenda for Change Grade 6 staff member (£29 per hour).
TABLE 35  Emergency department economic microcosting study costs
Item cost PoC (£)  (n = 122) SC (£) (n = 124)
Staff costsa 60.76 49.21
PoC tests (£21.33/panel) 38.13b 0
ED overheads (£5.38/hour) 20.81 17.32
Total costs
Mean 119.70 66.54
Minimum 52.04 26.41
Maximum 268.46 151.81
PoC, point of care; SC, standard care.
a  Source: RATPAC microcosting study.
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differences in mean cost per patient attributable to these two interventions were not statistically 
significant. A cost for ED stay for discharged patients was estimated on a pro rata basis using 
the ward cost for a day (£276.21) for patients who were discharged from the ED without any 
subsequent hospital admission. This cost was higher by £5.83 for patients discharged from the 
point-of-care group, who spent about a half-hour longer in the ED.
Table 37 shows resource use after the initial assessment. Items of resource use were costed 
only if they were chest pain related and could be matched with an appropriate unit cost. This 
explains why the numbers in this table for some items are slightly lower than corresponding 
data in the main outcomes analysis (Tables 16–21). Patients in the point-of-care group received 
more coronary care and intensive care, while patients in the standard-care group received more 
general inpatient care. None of these resulted in significant differences in mean cost, although 
the differences in the point estimates for costs relating to coronary care and intensive care were 
marked, with point-of-care panel assessment being associated with an additional £70.77 and 
£62.58 per patient, respectively. Patients in the point-of-care group received more outpatient 
follow-up. Standard care is associated with more nurse home visits and social work visits, but 
with relatively small differences in mean cost per patient.
Table 38 shows resource use and costs for community health service support use when missing 
values for each item are imputed by the mean cost for the corresponding treatment arm. 
Note that this approach usually underestimates the variability in the data so that p-values are 
slightly underestimated.
Table 39 shows the mean cost per patient by treatment group at each site and across all sites. 
Inferential analyses were conducted on imputed data; totals based on complete case means are 
included for comparison. Across all sites the mean cost per patient was higher in the point-of-
care group by £211.22 in the imputed analysis (p = 0.056). Mean differences at individual sites 
ranged from £214.49 less in the point-of-care group at Leeds to £646.57 more in the point-of-
care group at Edinburgh, with only the difference at Edinburgh being statistically significant 
(p = 0.025). An ANOVA test across centres (based on permuted test summed across the imputed 
data sets) yielded a p-value of 0.0803.
Tables 40 and 41 show the mean EQ-5D scores at 30 and 90 days using complete cases only (i.e. 
only those with data at both time points) and with imputation of missing values. There was no 
significant difference at either time point. Imputation did not markedly change the mean scores 
in either group at either time point.
TABLE 36  Other resource use at initial assessment, by treatment group
Resource item
No. of patients Frequencies Cost (£)
PoC SC PoCa SCa PoCa SCa p-valueb
Medications 827 891 2086 2112 5.56 5.21 0.703
Laboratory tests 1071 1075 2079 2546 28.58 38.00 < 0.001
ECGs 1125 1118 1411 1484 33.44 35.39 < 0.001
Angiograms 16 8 16 8 1.85 0.92 0.104
ED stayc 598 446 – – 40.36 34.53 < 0.001
PoC, point of care; SC, standard care.
a SC:  n = 1118, PoC: n = 1125.
b For  t-test.
c  Pro rata cost of hospital ward for patients not admitted.46 Results
Table 42 shows the total QALYs accrued (the difference) over 3 months at each site for both 
treatment groups. Data are reported assuming that EQ-5D was zero at baseline, although means 
for any baseline score between 0 and 1 can be estimated by adding a constant k/24, where k is 
the baseline EQ-5D score of interest. As 3 months is approximately one-quarter of a year, the 
maximum possible number of QALYs accrued is 0.25 (assuming EQ-5D was 1 at baseline). In 
practice, there is very little difference between treatment arms evident (a difference of 0.00273 
is equivalent to 1 day), and there were no significant differences in QALYs accrued at any site or 
across all sites.
TABLE 38  Non-hospital resource use: mean imputation analysis
Item
Resource use Cost (£)
PoC SC
PoC SC p-valuea Patients Frequency Patients Frequency
GP surgery visits  1125 2668 1118 2440 123.32 113.48 0.065
GP home visits 1125 166 1118 186 8.56 9.64 0.497
Nurse home visits 1125 206 1118 400 3.96 7.75 0.008
Social worker visits 1125 77 1118 226 1.95 5.75 0.040
Work time lost (days) 1125 1118 7.58 8.28 0.3776b
PoC, point of care; SC, standard care.
a  The p-value for t-test [permutation (non-parametric) tests also conducted and qualitative results coincide] unless specified.
b  The p-value for permutation of t-test.
TABLE 37  Non-ED resource use and costs, by treatment group
Itema
Resource use Cost (£)
PoC SC
PoC SC p-valueb Patients Frequency Patients Frequency
Coronary care days 47 176 31 104 174.56 103.79 0.064
Intensive care days 7 64 3 14 80.24 17.66 0.352
Other inpatient days 429 1353 564 1467 330.96 362.43 0.420
Outpatient attendances 191 222 155 183 35.18 27.67 0.045
Diagnostic tests (non-laboratory) 344 450 327 430 51.41 49.28 0.573
Interventions 47 54 38 40 149.83 91.25 0.061
Post-discharge events (ED 
attendances)
100 140 104 155 13.30 14.82 0.507
Community health supportc
GP surgery visits  562/626 1977 519/666 1816 154.36 150.85 0.646
GP home visits 44/553 98 47/535 109 10.28 11.82 0.602
Nurse home visits 44/554 128 46/529 262 5.00 10.72 0.046
Social worker visits 14/549 45 26/529 164 2.33 8.82 0.091
PoC, point of care; SC, standard care.
a  Costs of informal care excluded as it is outside the perspective of the study.
b The  p-value for t-test [permutation (non-parametric) tests also conducted and qualitative results coincide].
c  Complete case analysis: fraction is number of patients with events over number with completed items.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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The cost-effectiveness plane based on the resampled cost-effectiveness data points for the point-
of-care test strategy (Figure 6, with mean values shown by grey target) shows that, owing to the 
negative sign of the incremental QALYs, there is a high probability that the strategy is dominated 
TABLE 39  Total costs, by treatment group and site
PoC (£) SC (£)
Difference (95% CI) p-value n  Mean n Mean
Barnsley 162 1058.33 164 923.13 135.20
(–306.97 to 598.44)
0.538
Derriford 164 1466.81 164 1307.95 158.86
(–326.84 to 679.23)
0.529
Edinburgh 228 1356.35 224 709.78 646.57
(73.12 to 1612.71)
0.025
Frenchay 233 1162.53 231 1058.33 104.20
(–288.11 to 511.34)
0.625
Leeds 173 785.00 171 999.49 –214.49
(–657.10 to 132.56)
0.345
Leicester  165 1495.54 164 1115.41 380.13
(–181.53 to 914.82)
0.148
Total (imputed 
data)
1125 1217.14 1,118 1005.91 211.23
(–16.53 to 442.90)
0.056
Total (complete 
case means)
1216.18 1008.94 207.24
(2.98 to 431.62)
0.047
PoC, point of care; SC, standard care.
TABLE 40  European Quality of Life-5 Dimensions scores: complete case analysis
PoC SC
p-valuea n  Mean n Mean
Score at 1 month 697 0.747 650 0.761 0.369
Score at 3 months 697 0.753 650 0.759 0.710
PoC, point of care; SC, standard care.
a The  p-value for t-test [permutation (non-parametric) tests also conducted and qualitative results coincide].
TABLE 41  European Quality of Life-5 Dimensions scores: imputed data sets analysis
Item
PoC SC
p-valuea n Mean n Mean
Score at 1 month 1125 0.753 1118 0.769 0.158
Score at 3 months 1125 0.764 1118 0.772 0.433
PoC, point of care; SC, standard care.
a The  p-value for t-test [permutation (non-parametric) tests also conducted and qualitative results coincide].48 Results
(empirical probability 0.888). Conversely, the probability of the point-of-care test strategy being 
cost-effective at £20,000 per QALY is (understandably) very low (0.004).
Cost-effectiveness results are presented in Table 43. Empirical probabilities of a policy being 
dominated [i.e. has higher cost and is less effective than the index (standard care) policy], and 
of being cost-effective (i.e. having an incremental cost-effectiveness ratio no larger than £20,000 
when the policy is more effective), are also presented.
Table 43 also shows the results of two analyses used to explore whether the findings were robust 
to two important assumptions. First, we explored whether a cheaper point-of-care test could be 
TABLE 42  Total QALYs, by treatment group and site
PoC SC
Difference (95% CI) p-value n Mean n Mean
Barnsley 162 0.153 164 0.157 –0.004
(–0.016 to 0.010)
0.621
Derriford 164 0.158 164 0.156 0.002
(–0.011 to 0.013)
0.743
Edinburgh  228 0.158 224 0.162 –0.004
(–0.014 to 0.006)
0.529
Frenchay 233 0.157 234 0.163 –0.006
(–0.016 to 0.004)
0.267
Leeds 173 0.162 171 0.162 0.000
(–0.010 to 0.011)
0.687
Leicester  165 0.158 164 0.163 –0.005
(–0.015 to 0.006)
0.401
Total 1125 0.158 1118 0.161 –0.003
(–0.007 to 0.002)
0.250
PoC, point of care; SC, standard care.
FIGURE 6  Cost-effectiveness plane for point-of-care treatment strategy.
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cost-effective by assuming that the test performance for a single troponin test, which at £6.17 
incurs the lowest feasible point-of-care test cost, is the same as that of the trial strategy. In this 
scenario only costs would be affected, and test costs are reduced from £38.13 to £6.17, so that the 
mean cost difference would reduce to £179.26. Despite this, the probability of the point-of-care 
strategy being cost-effective remained low. Second, we explored whether excluding intensive care 
costs would alter the findings. Intensive care costs are only weakly related to the intervention and 
one patient in the point-of-care group had spent 52 days on intensive care, incurring substantial 
costs and increasing the variance of cost estimates. The results show that excluding intensive 
care costs reduced the mean cost per patient of point-of-care but did not markedly alter the 
probability that this strategy would be cost-effective.
These sensitivity analyses do not vary the results of the base case (i.e. trial) cost-effectiveness 
analysis, which might be expected as the alternative scenarios affect only costs.
Figure 7 shows estimated 95% confidence ellipses, assuming bivariate normality, of incremental 
costs and QALYs, for each of the hospital sites. Note that the plots are based on smaller sample 
sizes than the overall result and this is reflected in the higher variability. The plots generally 
reflect the overall result, and highlight, for example, the greater incremental cost variability of 
Edinburgh (where the patient with the long intensive care stay was recruited) and the possibility 
that, for Derriford or Leeds, the strategy may have a reasonable probability of being cost-effective.
Decision-analytic modelling
The parameters used in the model are shown in Appendix 4. The probabilistic analyses based on 
the decision-analytic model yielded a mean difference in costs (point of care minus standard 
care) of £169 (empirical 95% CI –£1229 to £1658) and in QALYs of –0.002 (95% CI –0.108 to 
0.104), which correspond reasonably with the trial-based results, particularly in the light of 
the simplifications outlined above (see Methods). The estimated probability that point-of-care 
panel assessment is cost-effective for a willingness to pay of £20,000 per QALY under these 
circumstances was 0.223. The model extrapolated to lifetime survival resulted in a mean cost 
difference of £329 (95% CI –£1312 to £2028) and corresponding value for QALYs of –0.087 (95% 
CI –12.3 to 12.2) accrued over a lifetime. The probability of cost-effectiveness of point-of-care 
panel assessment based on lifetime survival was estimated at 0.336.
TABLE 43  Cost and QALYs incremental differences
Policy
Incremental means Probability of
Cost (£) QALYs Being dominated
Cost-effectiveness at 
£20,000 per QALY
SC 0 0 – –
PoC 211.22 –0.0028154 0.888 0.004
PoC test using a single troponin test 179.26 –0.0028154 0.869 0.006
PoC costs excluding intensive care 153.59 –0.0028154 0.876 0.006
PoC, point of care; SC, standard care.50 Results
Evaluation of GRACE and TIMI scores
Table 44 shows the number and proportion of patients with and without a major adverse event 
up to 1 month in each quintile of the GRACE score and each category of the TIMI score. Table 45 
shows the same data for major adverse events up to 3 months. The proportion with a major 
adverse event at either 1 month or 3 months increases progressively with increasing quintiles 
of GRACE score regardless of the method used to incorporate troponin or the method used to 
analyse the data. The relationship between TIMI score and proportion with a major adverse event 
is not as clear, especially at 1 month. Patients with a TIMI score of 2 had the highest rate of major 
adverse events by 1 month.
Table 46 reports the area under the receiver-operator characteristic curve for GRACE and TIMI 
scores for predicting major adverse events up to 1 month and 3 months, and Figure 8 shows 
the curves. As before, these are presented for both methods of incorporating the troponin 
measurement and both methods of analysing the data. The method of analysis made little 
difference but the use of any troponin measurement resulted in consistently higher discriminant 
value than the use of the first troponin only. Both scores tended to predict events slightly better 
over the longer follow-up period. Overall, GRACE had better discriminant value for predicting 
adverse events than TIMI, although neither score predicted events with the kind of accuracy 
required to be clinically useful (i.e. with an area under the receiver-operator characteristic curve 
greater than 0.8). The area under the receiver-operator characteristic curve for age alone as a 
predictor was 0.66 for major adverse events up to 1 month and 0.69 for events up to 3 months. 
Hence, knowing the TIMI score appears to be no better than knowing the patient’s age for 
predicting subsequent major adverse events in this cohort.
FIGURE 7  Cost-effectiveness plane for point-of-care treatment strategy, by site.
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TABLE 44  Major adverse events up to 1 month by GRACE and TIMI score
Score No. of patients Major adverse event [n (%)] No major adverse event [n (%)]
GRACE score
Complete case analysis
Any troponin positive
< 60 280 0 280 (100.0)
60–79 402 5 (1.2) 397 (98.8)
80–89 251 3 (1.2) 248 (98.8)
90–109 384 11 (2.9) 373 (97.1)
> 109 422 19 (4.5) 403 (95.5)
First troponin positive
< 60 304 1 (0.3) 303 (99.7)
60–79 429 4 (0.9) 425 (99.1)
80–89 260 5 (1.9) 255 (98.1)
90–109 363 11 (3.0) 352 (97.0)
> 109 392 17 (4.3) 375 (95.7)
Imputed analysis
Any troponin positive
< 60 389 0 389 (100.0)
60–79 520 5 (1.0) 515 (99.0)
80–89 327 5 (1.5) 322 (98.5)
90–109 477 13 (2.7) 464 (97.3)
> 109 530 20 (3.8) 510 (96.2)
First troponin positive
< 60 414 1 (0.2) 413 (99.8)
60–79 547 4 (0.7) 543 (99.3)
80–89 338 7 (2.1) 331 (97.9)
90–109 459 13 (2.8) 446 (97.2)
> 109 485 18 (3.7) 467 (96.3)
TIMI score
Complete case analysis
Any troponin positive
0 764 5 (0.7) 759 (99.3)
1 565 14 (2.5) 551 (97.5)
2 314 13 (4.1) 301 (95.9)
3 106 4 (3.8) 102 (96.2)
4 or 5 33 1 (3.0) 32 (97.0)
First troponin positive
0 839 6 (0.7) 833 (99.3)
1 531 15 (2.8) 516 (97.2)
2 305 13 (4.3) 292 (95.7)
3 89 2 (2.2) 87 (97.8)
4 or 5 31 1 (3.2) 30 (96.8)
continued52 Results
TABLE 45  Major adverse events up to 3 months by GRACE and TIMI score
Score No. of patients Major adverse event [n (%)] No major adverse event [n (%)]
GRACE score
Complete case analysis
Any troponin positive
< 60 280 0 280 (100.0)
60–79 402 7 (1.7) 395 (98.3)
80–89 251 7 (2.8) 244 (97.2)
90–109 384 12 (3.1) 372 (96.9)
> 109 422 29 (6.9) 393 (93.1)
First troponin positive
< 60 304 1 (0.3) 303 (99.7)
60–79 429 6 (1.4) 423 (98.6)
80–89 260 9 (3.5) 251 (96.5)
90–109 363 12 (3.3) 351 (96.7)
> 109 392 27 (6.9) 365 (93.1)
Imputed analysis
Any troponin positive
< 60 389 0 389 (100.0)
60–79 520 7 (1.3) 513 (98.7)
80–89 327 10 (3.1) 317 (96.9)
90–109 477 14 (2.9) 463 (97.1)
> 109 530 31 (5.8) 499 (94.2)
First troponin positive
< 60 414 1 (0.2) 413 (99.8)
60–79 547 6 (1.1) 541 (98.9)
80–89 338 12 (3.6) 326 (96.4)
90–109 459 15 (3.3) 444 (96.7)
> 109 485 28 (5.8) 457 (94.2)
Score No. of patients Major adverse event [n (%)] No major adverse event [n (%)]
Imputed analysis
Any troponin positive
0 969 6 (0.6) 963 (99.4)
1 695 15 (2.2) 680 (97.8)
2 403 16 (4.0) 387 (96.0)
3 138 5 (3.6) 133 (96.4)
4 or 5 38 1 (2.6) 37 (97.4)
First troponin positive
0 1046 8 (0.8) 1038 (99.2)
1 656 15 (2.3) 641 (97.7)
2 386 16 (4.1) 370 (95.9)
3 120 3 (2.5) 117 (97.5)
4 or 5 35 1 (2.9) 34 (97.1)
TABLE 44  Major adverse events up to 1 month by GRACE and TIMI score (continued)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Score No. of patients Major adverse event [n (%)] No major adverse event [n (%)]
TIMI score
Complete case analysis
Any troponin positive
0 764 8 (1.0) 756 (99.0)
1 565 17 (3.0) 548 (97.0)
2 314 18 (5.7) 296 (94.3)
3 106 6 (5.7) 100 (94.3)
4 or 5 33 2 (6.1) 31 (93.9)
First troponin positive
0 839 9 (1.1) 830 (98.9)
1 531 20 (3.8) 511 (96.2)
2 305 16 (5.2) 289 (94.8)
3 89 4 (4.5) 85 (95.5)
4 or 5 31 2 (6.5) 29 (93.5)
Imputed analysis
Any troponin positive
0 969 9 (0.9) 960 (99.1)
1 695 19 (2.7) 676 (97.3)
2 403 24 (6.0) 379 (94.0)
3 138 8 (5.8) 130 (94.2)
4 or 5 38 2 (5.3) 36 (94.7)
Troponin positive
0 1046 11 (1.1) 1035 (98.9)
1 656 22 (3.4) 634 (96.6)
2 386 21 (5.4) 365 (94.6)
3 120 6 (5.0) 114 (95.0)
4 or 5 35 2 (5.7) 33 (94.3)
TABLE 45  Major adverse events up to 3 months by GRACE and TIMI score (continued)54 Results
TABLE 46  Receiver-operator characteristic curve analysis of GRACE and TIMI scores
Area under 
the ROC 
curve
95% CI
Lower Upper
1 month
GRACE score Complete case analysis Any troponin positive 0.722 0.700 0.743
First troponin positive 0.706 0.683 0.727
Imputed analysis Any troponin positive 0.717 0.698 0.735
First troponin positive 0.705 0.686 0.724
TIMI score Complete case analysis Any troponin positive 0.678 0.656 0.700
First troponin positive 0.668 0.645 0.689
Imputed analysis Any troponin positive 0.682 0.662 0.701
First troponin positive 0.665 0.645 0.684
3 months
GRACE score Complete case analysis Any troponin positive 0.731 0.709 0.752
First troponin positive 0.721 0.699 0.742
Imputed analysis Any troponin positive 0.726 0.707 0.745
First troponin positive 0.715 0.696 0.734
TIMI score Complete case analysis Any troponin positive 0.680 0.657 0.701
First troponin positive 0.668 0.645 0.689
Imputed analysis Any troponin positive 0.693 0.674 0.712
First troponin positive 0.675 0.655 0.694
ROC, receiver-operator characteristic.
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FIGURE 8  Receiver-operator characteristic curves for GRACE and TIMI scores. (a) TIMI score and 30-day major 
adverse events (MAEs). (b) GRACE score and 30-day MAEs. (c) TIMI score and 90-day MAEs. (d) GRACE score and 
90-day MAEs.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
57   Health Technology Assessment 2011; Vol. 15: No. 23 DOI: 10.3310/hta15230
Chapter 4  
Discussion
Effectiveness of point-of-care panel assessment
Point-of-care panel assessment with CK-MB (mass), myoglobin and troponin at baseline 
and 90 minutes increased the proportion of patients with acute undifferentiated chest pain 
successfully discharged home after ED assessment (defined as having left the hospital or with a 
decision to discharge by 4 hours after attendance and no major adverse event over the following 
3 months). The difference in the proportion of patients in hospital persisted until 24 hours after 
attendance and resulted in a shorter median length of initial hospital stay for patients in the 
point-of-care group and a greater proportion of the point-of care group having no inpatient days 
over the 3 months of the trial. However, it did not lead to any difference in the mean length of 
initial hospital stay or any difference in the mean number of inpatient days over the 3-month 
follow-up. This appeared to be due to a small number of patients with very long hospital stays 
and/or large number of inpatient-days that increased the variance for these variables and which 
were over-represented in the point-of-care group.
These findings suggest that the benefit of point-of-care panel assessment may depend upon one’s 
perspective. The proportion successfully discharged and the median length of stay describe the 
experience of the typical patient. Patients and clinicians may perceive benefit from point-of-care 
panel assessment, reducing the proportion of patients admitted and the duration of hospital stay 
for a typical patient. Hospital bed use is best estimated from the mean length of stay and mean 
number of inpatient days. When these are multiplied by the number of patients they produce an 
estimate of the total bed-days used by the patient cohort. Point-of-care panel assessment may 
reduce patient turnover (i.e. the number of patients being admitted and using hospital beds), but 
our data suggest that it will not significantly reduce hospital bed use.
Point-of-care panel assessment was associated with increased use of coronary care and 
administration of clopidogrel, but reduced use of aspirin. The last two findings appear to match 
each other, with 5% more patients in the point-of-care group receiving clopidogrel and 5% fewer 
receiving aspirin. These findings suggest a potential benefit from point-of-care panel assessment 
but one that is difficult to extrapolate into measures that are meaningful to the patient, such as 
improved survival or quality of life. They do, however, incur additional costs and are considered 
in the economic analysis.
Point-of-care panel assessment was not associated with any significant differences in 
investigations, cardiac interventions, ED attendances and subsequent hospital admissions over 
the following 3 months, although the non-significant differences in these areas of resource use 
contributed to the economic analysis. Point-of-care panel assessment was associated with a 
borderline significant increase in chest pain-related outpatient attendances, but this was one of 
many hypothesis tests and could be a chance finding.
From the patient’s perspective, point-of-care panel assessment was associated with no significant 
differences in health utility at 1 or 3 months, or time taken off work. It was associated with higher 
overall satisfaction with care, with more patients in the point-of-care group assessing their 
care as being excellent or very good, and fewer assessing it as good, fair or poor. Point-of-care 58 Discussion
panel assessment received a more favourable rating on 2 of the 10 dimensions of satisfaction 
measured: the urgency of assessment and the personal interest shown in the patient and his or 
her medical problems. There were no significant differences between the study groups on the 
other dimensions.
These findings suggest a modest patient preference for point-of-care panel assessment. However, 
patients were not blinded and would have been aware of whether they were receiving the 
experimental intervention or standard care. Their preference for point-of-care panel assessment 
may therefore reflect a positive response to receiving the ‘new’ intervention in a trial rather than a 
specific preference for the intervention.
Major adverse event rates were low, with only 62 out of 2243 patients (3%) having any major 
adverse event over 3 months, including only eight deaths and 10 non-fatal MIs. There were no 
significant differences in overall major adverse event rates or the rates of any individual event. CIs 
for adverse event rates were wide and the study was only originally powered to detect a relatively 
high 2% absolute increase in major adverse event rates.
We looked in detail at the major adverse events occurring in patients who were discharged 
after ED assessment, as these are the patients in whom a causal link between initial diagnostic 
assessment and major adverse event might be strongest. For example, if a patient was discharged 
after ED assessment had failed to identify MI then this could increase the risk of adverse 
outcome. Four patients in the point-of-care arm and one in the standard-care arm suffered 
adverse events after ED discharge. In all but one case the adverse event occurred more than 
1 month after initial assessment. This relatively long time between intervention and outcome 
makes it difficult to assert a causal link. Furthermore, all five patients presented relatively late 
after their pain and received biomarker testing after a relatively long delay from worst symptoms. 
It is therefore very unlikely that any of these patients had a missed diagnosis of MI at their 
initial presentation.
Cost-effectiveness of point-of-care panel assessment
Overall, the economic analysis showed that point-of-care panel assessment was unlikely to be 
cost-effective compared with standard care. The main analysis produced a 0.888 probability that 
standard care dominated point-of-care panel assessment (i.e. was cheaper and more effective). 
The cost-effectiveness analysis was planned as an analysis of the incremental cost per QALY of 
point-of-care panel assessment. However, the main difference between the strategies and the 
main driver of cost-effectiveness was cost. The difference in QALYs between the two groups 
was small (0.003 QALYs) and non-significant (p = 0.250). The difference in costs between the 
two groups was £211 and bordered on being significant (p = 0.056). Hence, it appears that 
point-of-care panel assessment may increase costs despite reducing hospital admissions and 
inpatient days.
There appear to be a number of reasons for this. First, point-of-care panel assessment is 
associated with an additional £53 per patient for initial ED assessment. Most of this (£38) is 
related to the point-of-care machine, but additional staff time to undertake the tests also adds to 
the costs. It is possible that using the machine for other ED patients (thus reducing the amount 
charged for equipment) or using a simple protocol (such as a single troponin measurement) 
could reduce the additional costs associated with point-of-care panel assessment. We undertook a 
sensitivity analysis assuming that the machine costs were only £6.17 per patient instead of £38.13, 
but this did not markedly change the overall result, with there still being a 0.869 probability that 
standard care was dominant.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Point-of-care panel assessment was also associated with markedly higher mean costs for cardiac 
interventions, coronary care and intensive care. These failed to compensate for a £31 per patient 
saving from reduced inpatient days. The cost differences were not statistically significant but still 
added to the overall cost difference between point-of-care panel assessment and standard care. It 
could be argued that intensive care admissions are unlikely to be related to the initial diagnostic 
process. Indeed, one patient who suffered serious complications after CABG accounted for most 
of the intensive care days. We therefore undertook a sensitivity analysis with intensive care costs 
excluded. Although the difference in costs was reduced from £211 to £154, the probability of 
standard care being dominant remained high at 0.876.
The finding that there is a very low probability of point-of-care panel assessment being cost-
effective is perhaps surprising given that the trial showed it was associated with a statistically 
significant improvement in its primary outcome measure, the proportion of patients successfully 
discharged home. However, it appears that earlier diagnosis may have an impact on other clinical 
decisions in addition to discharge home from the ED. In particular, admissions to coronary 
care and cardiac interventions were more frequent in the point-of-care group. One possible 
explanation for the increase in coronary care costs, for example, is that early recognition of 
troponin elevation may prompt admission to the coronary care unit, whereas an elevated 12-hour 
troponin after admission to a general ward is unlikely to prompt transfer to coronary care.
Variation between the participating sites
The analysis of the primary outcome and cost-effectiveness analysis showed marked 
differences between the participating sites. As described in the primary efficacy results section 
(see Chapter 3), these differences are probably due to differences in the facilities available for 
managing patients with chest pain and the standard care processes normally undertaken at the 
hospital. All hospitals, except Leicester, showed an effect from point-of-care panel assessment 
upon the primary outcome. The most marked effect occurred at hospitals in which chest pain 
patients were subject to a target of spending no more than 4 hours in the ED and standard care 
involved a 12-hour troponin. In these hospitals there was a significant difference in the primary 
outcome, which persisted until about 24 hours after attendance. At Leeds, where all patients 
with chest pain were cared for on a clinical decision unit that was not subject to a 4-hour target, 
the effect of point-of-care panel assessment was delayed until around 6 hours after attendance. 
At Derriford, where the standard care guidelines recommended a 6-hour troponin, the effect of 
point-of-care panel assessment was short-lived and not noticeable after 8 hours from attendance. 
The exception of Leicester is probably explained by trial factors. The Leicester Research Office 
stipulated that only doctors who had received full training in GCP could undertake trial 
recruitment. This meant that the research nurses were overwhelmingly responsible for recruiting 
patients and producing point-of-care test results. This probably meant that the clinical decision-
makers (doctors) were not engaged in the trial and did not act on the test results.
The differences between the sites in the primary outcome are not reflected in differences in mean 
costs per patient. This is perhaps unsurprising as the overall analysis showed that the increase 
in the proportion successfully discharged with point-of-care panel assessment did not translate 
into cost savings. Mean costs were higher in the point-of-care arm at five hospitals and lower at 
one. It is possible that the overall conclusion that point-of-care panel assessment is unlikely to 
be cost-effective does not apply at some of the sites, such as Leeds and Derriford. However, we 
should be careful about drawing conclusions from individual site cost data because cost variances 
are large and most of the cost differences at individual sites were not statistically significant. 
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Edinburgh, in particular, can be at least in part accounted for by two patients in the point-of-care 
arm with very high costs due to prolonged hospital stays.
However, in general terms it is possible that inpatient treatment patterns differ between hospitals 
and that in some settings point-of-care panel assessment in the ED does not lead to higher costs 
of inpatient care. If this were the case then point-of-care would have the potential to be cost-
effective, as is suggested with the confidence ellipses in Figure 7. Previous work on chest pain 
units has tried to identify the combination of costs and admission rates that would make such 
initiatives cost-effective.53 Similar studies could be worthwhile here.
Variation over time
The effect of point-of-care panel assessment could change over time as a result of clinicians 
becoming familiar with the technology and changing their decision-making in response to the 
point-of-care results. In particular, the change in the recommended decision-making threshold 
for point-of-care troponin could have changed the proportion of patients successfully discharged 
after point-of-care assessment. Conversely, standard care could change over time and start to 
mimic point-of-care panel assessment, thus leading to contamination of the control group and a 
bias towards no effect.
We analysed the primary outcome and deviations from the recommended point-of-care protocol 
at quarterly intervals to explore whether the effect of point-of-care panel assessment changed 
over time. Only two patients in the control group received the combination of tests used in the 
point-of-care machine (CK-MB, myoglobin and troponin) either from the machine itself or 
from the hospital laboratory, so we did not examine deviations from standard care over time. 
Deviations from the recommended point-of-care protocol remained relatively constant over 
time, so there was no evidence that developing experience with the technology eliminated these 
problems. However, the proportion successfully discharged in the point-of-care arm decreased 
during the middle third of the trial and increased in the last third, while the proportion 
successfully discharged in the standard-care arm steadily fell over the trial. The first finding may 
be explained by the amendment to the troponin threshold in the recommended point-of-care 
protocol that advised discharge instead of admission for patients with a non-rising troponin in 
the range 0.03–0.07 µg/l. The second finding may be due to clinical staff becoming progressively 
more cautious during the trial. However, we must be careful not to overinterpret these findings as 
they are based on relatively small numbers.
Other studies of point-of-care cardiac markers
The RATPAC trial is the first randomised trial to evaluate whether a panel of point-of-care 
cardiac markers designed to rule out MI in ED patients with acute chest pain can change clinical 
decision-making and lead to changes in patient care. Previous studies22,23 have evaluated the 
point-of-care panel and laboratory testing in the same cohort to compare the times taken to 
receive a test result and have shown that turnaround times are shorter with point-of-care testing, 
but few studies have compared practice in cohorts with or without point-of-care testing. Ng et 
al.24 compared management with the point-of-care panel with previous practice without the test 
and found a 40% reduction in coronary care unit admissions. This contrasts with RATPAC, in 
which we found that point-of-care panel assessment was associated with increased coronary 
care use. There are two potential explanations for this discrepancy. First, the study by Ng et 
al.24 may have been confounded by changes in practice occurring over time that would have 
been controlled for in RATPAC by the randomised design. Second, the study by Ng et al.24 was © Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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undertaken in a health-care system and patient cohort with much higher coronary care use, 
so there was much greater potential to reduce admissions. This illustrates the difficulties in 
extrapolating findings relating to health service use between diverse settings.
Other studies, including randomised trials, have evaluated point-of-care testing by directly 
comparing use of a point-of-care troponin assay with use of a laboratory assay, rather than 
evaluating a point-of-care protocol as we did in RATPAC. As outlined in Chapter 1, such studies 
have produced mixed results, with Collinson et al.12 finding reduced length of coronary care unit 
stay and overall hospital stay, Renaud et al.13 reporting reduced time to anti-ischaemic therapy 
and physician notification of results, but no change in ED length of stay or patient outcomes, and 
Ryan et al.14 finding that the effect of point-of-care testing varied between settings, with length 
of stay in the ED being increased in one hospital and decreased in another. These studies are not 
directly comparable with RATPAC because they compare only the process of using a point-of-
care versus a laboratory assay, whereas RATPAC evaluated a point-of-care protocol involving 
a specific panel of tests designed to rule out MI in patients with acute chest pain. However, the 
inconsistencies noted between the findings of these studies and the variability between the sites 
involved in RATPAC suggest that the effects of point-of-care testing are inconsistent, whether one 
is simply examining the effect of point-of-care testing itself or point-of-care testing is being used 
to deliver a specific protocol.
Strengths and weaknesses of the study
As a randomised trial, RATPAC has the strength of providing an unbiased comparison between 
the point-of-care protocol and standard care. Allocation of treatment group was concealed 
until the patient was irreversibly entered into the trial and the low rate of withdrawals before 
the primary outcome, coupled with analysis being as randomised, meant that the benefits of 
randomisation were preserved. The trial was pragmatic, in that the only difference between study 
groups was the availability of point-of-care panel assessment, and involved six diverse hospitals, 
so findings from the study can be generalised across the NHS. We measured a range of important 
outcomes and undertook cost-effectiveness analysis using data from real patients, thus avoiding 
having to make assumptions about how patients would be managed. The economic analysis used 
standard methods recommended by NICE41 to allow comparison of the cost-effectiveness of 
point-of-care panel assessment with other competing demands for NHS resources.
The study also had a number of limitations that should be taken into account when interpreting 
the findings. We obviously could not blind patients or carers to whether they had been 
randomised to intervention or control. In some respects this does not matter for a pragmatic 
trial where we are simply interested in whether an intervention works rather than how or why 
it works, but it may be important in interpreting patient-reported outcomes. Patients who 
are randomised to the standard-care group may feel that they have had a potentially valuable 
intervention withheld and may respond negatively when asked for their opinion. Response 
rates for the patient questionnaire were, as anticipated, around 70%, so there is the potential 
for responder bias. It is notable in this respect that response rates were lower in the standard-
care group, perhaps reflecting a reduced level of engagement in those who did not receive the 
study intervention.
Point-of-care testing, and troponin assays in particular, is a rapidly developing area of technology. 
This created inevitable difficulties in selecting the appropriate machine and assay to use, and 
in providing guidance for the interpretation of results. We believe that our decision to change 
from the Biosite troponin assay to the more sensitive Stratus CS Analyser has been vindicated 
by recent publications7,8 that show the value of high-sensitivity troponin assays and suggest that 62 Discussion
these will become standard. However, working with a relatively new assay created problems with 
interpreting low positive results and led to our having to change the recommended protocol 
during the trial. These issues are not limited to the RATPAC trial and the introduction of highly 
sensitive troponin assays into practice is likely to be complicated by difficulties deciding how 
to manage patients with levels close to, or just below, the diagnostic threshold. Thus, it can 
be argued that the difficulties encountered in the trial in terms of machine malfunction and 
assay interpretation merely reflect the difficulties encountered in normal practice. However, an 
inevitable side effect of undertaking evaluation of a developing technology may be a degree of 
bias against the new technology, in that clinicians may take time to develop familiarity and the 
technology may ultimately perform better when it is in widespread use.
The trial was terminated before the target of 3130 patients was reached so it did not have the 
originally planned power. For the primary outcome this was compensated by the actual control 
admission rate being higher than the original estimate of the baseline admission rate. The trial 
was originally powered to detect a doubling of the major adverse event rate from 2% to 4%. In 
the event, at the time it was terminated it only had conditional power of < 10% to detect such 
a difference. It is therefore possible that point-of-care panel assessment may achieve increased 
successful discharges at the expense of an increase in major adverse events that the trial was not 
powered to detect. However, detailed examination of the adverse events suggests that there is 
unlikely to be a strong association between point-of-care panel assessment and adverse events. 
Most of the events occurred in patients who had been admitted after ED assessment. Of the five 
cases that occurred after discharge, only one occurred within the time span of a typical hospital 
admission. In general, the low adverse event rate in this study, especially deaths and non-fatal 
MI, should provide some reassurance that in this selected low-risk population the risk of adverse 
outcome shortly after attendance is very low.
The trial was deliberately designed as a pragmatic evaluation of a specific point-of-care protocol. 
The intervention was therefore a composite of the point-of-care technology and the cardiac 
marker panel. This type of pragmatic evaluation carries the disadvantage that we cannot clearly 
isolate which element of the intervention is effective (or ineffective). It is thus possible that 
the effects recorded in this study were due to the biomarker panel, rather than point-of-care 
technology, and could have been achieved using laboratory assays if turnaround times were 
sufficiently rapid.
The trial was undertaken at six diverse NHS hospitals and all participating centres contributed 
substantially to recruitment. The variation in the participating hospitals is likely to reflect 
variation in practice across the NHS.11 This variation means that although we may conclude that 
out findings apply in general across the NHS it is possible that point-of-care panel assessment 
may be more or less effective or cost-effective in specific hospitals. The methods used for cost-
effectiveness in particular are appropriate for NHS-wide decision-making but may not reflect the 
costs, effects and priorities of specific individual hospitals.
Imputation methods were used to estimate missing values on the basis of observed values. Recent 
methods favour the approach of generating multiple imputed data sets (multiple imputation). 
The main potential limitation of multiple imputation arises from the implicit assumption that 
the observed data are representative of those that are missing. In other words, these data must 
be missing at random. With regard to the imputation of staff costs using the microcosting study 
data, it is likely that this assumption holds, as the sample on which this study was conducted 
was chosen at random. In the case of the imputation of community health service costs, it may 
be that the assumption is more tenuous. For example, it may be that patients who are well are 
less likely to respond to the follow-up survey. Imputation may overestimate costs in these cases. 
On the other hand, severely ill patients may also have higher rates of non-response. In this case, © Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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imputation would probably underestimate costs. However, given the follow-up procedures of the 
RATPAC study, it is less likely that data from such patients were not recorded.
Other limitations of imputation methods include small numbers and a proportion of missing 
values higher than some percentage, typically set at 30%. In the case of the staff costs imputed 
from the microcosting data, this assumption is violated, as the missing data rate is about 90%. 
However, the method of imputation used in this case was one of choosing the value from the 
patient with complete data which matches closest that of the incomplete case, which is less prone 
to result in a biased estimate, although it may result in underestimation of the variability.
Implications for practice
The RATPAC trial has shown that point-of-care panel assessment with CK-MB (mass), 
myoglobin and troponin leads to increased successful discharge after ED assessment, but 
probably costs more than standard care, and is unlikely to be considered a cost-effective use 
of NHS resources. This means that from an NHS perspective it would not be appropriate to 
recommend widespread adoption of the point-of-care panel unless specific reasons can be 
identified as to why it might be worth paying more to reduce the proportion of patients requiring 
hospital admission. From the perspective of an individual hospital, the decision of whether or not 
to use the point-of-care panel will depend upon the specific needs of the ED and acute specialties, 
and whether it may be considered worthwhile to pay the potential additional costs of point-of-
care panel assessment to achieve a specific service outcome, such as discharging more patients 
from the ED within the 4-hour time frame.
It is important to recognise that RATPAC evaluated a specific point-of-care combination for a 
specific purpose and that care should be taken not to extrapolate findings beyond this specific 
role. The RATPAC trial results suggest that a rule-out diagnostic testing protocol, which would 
be expected to lead to a substantial reduction in admissions, may, in practice, have only a modest 
effect and that a reduction in hospital admissions may not lead to health service cost savings. 
Although these findings may provide some useful insights when considering the wider role of 
point-of-care testing, they should not be extrapolated to all point-of-care tests in all settings.
Other findings from the RATPAC trial may have implications for practice and future 
developments in chest pain care. In particular, the very low rate of adverse events and the 
observation that most occur after the typical time span of hospital admission suggest that the 
value of hospital admission for these selected low-risk patients should be brought into question. 
Most of the investigations and interventions that may benefit patients can be delivered without 
hospital admission. If the purpose of hospital admission is simply to monitor patients thought 
to be at risk of adverse outcome then the data from this study suggest that admission for this 
purpose is unlikely to be worthwhile.
Implications for future research
The very low adverse event rates suggest that further research is required to evaluate the benefit 
of hospital admission and explore ways of managing acute chest pain that do not require hospital 
admission. RATPAC has shown that rapid diagnostic testing can make a modest impact upon 
hospital admissions. It may be that a substantial reduction in admissions can be achieved only 
through a fundamental restructuring of the way in which acute chest pain is assessed. This 
would involve moving from a ‘rule-out’ approach, where the aim is to identify low-risk patients 
who can be discharged home (with the rest being admitted), to a ‘rule-in’ approach, where the 64 Discussion
aim is to identify high-risk patients for hospital admission and treatment (with the rest being 
discharged home).
The RATPAC proposal recognised that this is a rapidly developing field and made provisions 
for future studies accordingly. We have stored blood samples from all participants in the point-
of-care group and will be using these samples to test new and emerging assays. This should 
be coupled with economic evaluation and modelling to explore the potential impact of new 
early biomarkers with different levels of sensitivity and specificity. Development of biomarkers 
has tended to accept loss of specificity in the attempt to optimise sensitivity. However, poor 
specificity has potentially important economic consequences that need to be explored and 
better understood.
Analysis of the individual sites involved in the RATPAC trial showed marked variation in 
standard practice and in the effect of the intervention upon the primary outcome. This suggests 
that point-of-care panel assessment could be more effective or cost-effective in specific settings. 
Further research should be undertaken to assess in what circumstances point-of-care panel 
assessment could be effective and cost-effective.
Analysis of GRACE and TIMI scores
We undertook this analysis as a secondary objective of the study unrelated to the primary 
objectives of evaluating point-of-care panel assessment. The GRACE and TIMI scores have been 
developed and validated on patients with diagnosed ACS to predict adverse events, usually up 
to 1 month. Our analysis suggests that they have limited prognostic value in low-risk patients 
with undifferentiated chest pain, with TIMI performing no better than patient age as a predictor 
and GRACE performing only slightly better (and also being more complex to calculate). This 
is perhaps not surprising since both were developed in populations with diagnosed ACS and a 
high risk of major adverse events. Developing a new clinical risk score in the low-risk population 
with undifferentiated chest pain may produce an instrument with greater prognostic value. 
Alternatively, it could be argued that the risk of adverse outcome in this population is so low 
that attempts to discriminate between those at very low risk and those at moderately low risk are 
unlikely to be successful.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Chapter 5  
Conclusions
P
oint-of-care panel assessment with CK-MB (mass), myoglobin and troponin increases the 
proportion of patients with acute undifferentiated chest pain who are successfully discharged 
home after ED assessment. This leads to a reduced proportion of patients being in hospital at any 
time over the next 3 months and a reduced median length of initial hospital stay, but no change 
in mean hospital stay or inpatient days. Point-of-care panel assessment is also associated with 
increased use of coronary care and may be associated with increased use of other interventions. 
It is unlikely to be considered cost-effective in the NHS, with a 0.888 probability that standard 
care is dominant. Cost-effectiveness is mainly driven by differences in mean cost, with point 
estimates suggesting that point-of-care panel assessment is £211 per patient more expensive than 
standard care.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Appendix 1  
Point-of-care protocol
Step 1
  ■ Collect an Investigation Pack from near RATPAC machine (Stratus CS Analyser).
  ■ Contains two green top tubes, two yellow top tubes, four small clear top tubes, two rotors, 
two cannulae, one Lab Form.
Note: the small tubes are for the labs, please do not remove from bag.
Step 2 – sample 1
  ■ Take point-of-care (PoC) blood samples (one yellow top and one green top) and routine 
bloods (normal tubes).
  ■ Label the yellow top sample with bar code and attach corresponding bar code label to Lab 
Form in pack.
  ■ Label green top sample with same bar code.
  ■ Scan bar coded green top tube in Stratus.
  ■ Enter patient study number (given by randomisation system) into Stratus and also add to 
Lab Form.
  ■ Please process green top sample in Stratus within 20 minutes.
  ■ Return yellow top sample and Lab Form to pack and store in fridge.
Step 3
  ■ Collect three reagent strips from fridge: troponin I (green), myoglobin (red), creatine kinase 
MB (CK-MB) (blue).
  ■ Invert green top tube gently several times (do not shake).
  ■ Process green top tube in Stratus as per instructions.
  ■ Results produced in 20 minutes.
  ■ After processing remove cannula unit and tube from the Stratus and discard appropriately.
Step 4 – interpretation of sample 1 results
  ■ Fix results slip in patient notes (important):
  – Troponin I ≥ 0.03 µg/l = positive result. Admit to hospital.
  – If no detectable troponin or < 0.03 µg/l = negative result. Finish assessing patient for 
90 minutes then take sample 2.76 Appendix 1
Step 5 – sample 2
  ■ At least 90 minutes from first sample, take second blood samples (one yellow top and one 
green top).
  ■ Label as before with corresponding bar codes on tubes and Lab Form.
  ■ Return yellow top to pack and store in fridge.
  ■ Process green top as before in Stratus.
  ■ Results produced in 20 minutes – keep printout with notes again.
Step 6
  ■ Remove cannula unit and tube from the Stratus and discard appropriately.
  ■ Add corresponding small labels (without bar code) to two small tubes for each yellow 
top sample.
  ■ Send tubes in pack with Lab Form to Clinical Biochemistry Lab (within 12 hours).
Note: Ignore remaining labels.
Step 7 – interpretation of sample results
  ■ Calculate CK-MB (mass) gradient = second CK-MB (mass) – first CK-MB (mass), for 
example 4.52 – 3.11 = 1.41 (negative).
  ■ Calculate percentage increase in myoglobin (m) = 100 × [(second m – first m)/first m], for 
example 100 × [(40 – 25)/25] = 60% (positive).
i.  If any of the following, admit to hospital (positive cardiac markers):
  – troponin I ≥ 0.03 µg/l
  – CK-MB (mass) > 5 µg/l on both samples
  – CK-MB (mass) gradient on second sample 1.6 µg/l higher than first sample
  – myoglobin on second sample 25% higher than first sample.
ii.  If cardiac markers negative, consider for discharge home.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 2  
Futility analysis
1.  Following the problems surrounding the inadvertent release of some RATPAC data to the 
HTA, Professor Tom Walley, Director of the HTA programme, asked me to act as an interim 
chair of RATPAC’s Data Monitoring and Ethics Committee (DMEC) in order to advise on 
whether the data supported the extension request.
2.  I have met the RATPAC statisticians and reviewed the method that they used to calculate 
the conditional power of RATPAC. They used a method favoured by HTA, by calculating 
the power of achieving a statistically significant result given the current data and accruing 
new data up to the proposed sample size in accordance with the effect size specified in the 
alternative hypothesis in the protocol.
3.  The current conditional power for the primary outcome (discharge home from the ED) 
recalculated using data to May 2009 is > 99.9%. The conditional power against the one 
secondary outcome that was originally powered in the protocol, major cardiac events, is 
< 10%. The current conditional power cannot be calculated for other secondary outcomes as 
no effect sizes were specified in alternative hypotheses in the protocol.
4.  The conditional power calculation suggests that there could be a case for stopping for 
efficacy. There are no specific efficacy stopping criteria approved by the RATPAC DMEC in 
their charter, and this was appropriate because the primary outcome is not related to any 
direct clinical end point. Nevertheless, the absence of such criteria cannot be taken to mean 
that the trial should continue irrespective of any possible outcome, and the charter makes it 
clear that the DMEC can recommend stopping if the results are ‘convincing’ or futile.
5.  In effect, the futility analysis suggests that the data must already be highly significant and that 
there is no chance that future data could change the result. This is not a situation that I had 
ever envisaged, but is, in fact, simply another type of futility.*
6.  There are some other important considerations. First, the trial is being operated in several 
centres and the statisticians tell me that the results are not uniform across the centres, so 
that there may be important information on the variation in effect. Second, there are the 
other secondary outcomes, such as EQ-5D scores, satisfaction with care, re-attendance and 
readmission, which we know nothing about. Most importantly, the question of the cost-
effectiveness of the intervention may not have been resolved, and this is the critical outcome 
for the NHS.
7.  In summary, there are grounds for stopping the trial for futility. There is no chance that 
future data can change the result for the primary end point. However, as with all trials, 
RATPAC is also providing a great deal of other information on variability between centres, 
subgroups, and important secondary end points, whose current status we do not know about. 
The value of this information has to be weighed against the cost of the extension request.
Jon Nicholl
Acting as the interim chair of the RATPAC DMEC
12 May 2009
*Futility is usually understood to mean that there is little or no chance that future data could 
lead to a significant result. However, what we should mean by futility is that there is little or no 
chance future data could change the result. Thus, continuing a trial with a significant result that 
cannot be changed is as futile as continuing a trial with a non-significant result that cannot be 
changed. This is not the same as stopping for efficacy. Stopping for efficacy is based on a test of 78 Appendix 2
the results under H0, not on the conditional power of achieving a significant result under H1. 
It is possible to stop for efficacy, even though it would not be technically futile to continue (i.e. 
the result could change). It is also possible to set the stopping rules for efficacy so tight that the 
reverse could happen, i.e. it is technically futile to continue though the efficacy stopping rule has 
not been reached.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Appendix 3  
Primary outcome details at each 
hospital
Supplemental tables
TABLE 47  Primary outcome at Barnsley
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 110 (68) 43 (26) 153 (47)
Not successfully discharged 52 (32) 121 (74) 173 (53)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 50 (31) 121 (74) 171 (52)
Initially discharged but re-attended with major adverse event 2 (1) 0 2 (1)
Discharge success by initial status
Initially discharged 112 (69) 43 (26) 155 (48)
Not in hospital at 4 hours 105 (65) 43 (26) 148 (45)
In hospital at 4 hours, decision made to discharge 7 (4) 0 7 (2)
PoC, point of care; SC, standard care.
OR = 5.95 (95% CI 3.69 to 9.61), p < 0.001.
TABLE 48  Primary outcome at Derriford
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 43 (26) 21 (13) 64 (20)
No successfully discharged 121 (74) 143 (87) 264 (80)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 121 (74) 142 (87) 263 (80)
Initially discharged but re-attended with major adverse event 0 1 (1) 1 (< 1)
Discharge success by initial status
Initially discharged 43 (26) 22 (13) 65 (20)
Not in hospital at 4 hours 29 (18) 18 (11) 47 (14)
In hospital at 4 hours, decision made to discharge 14 (9) 4 (2) 18 (5)
PoC, point of care; SC, standard care.
OR = 2.42 (95% CI 1.36 to 4.30), p = 0.003.80 Appendix 3
TABLE 49  Primary outcome at Edinburgh
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 104 (46) 16 (7) 120 (27)
Not successfully discharged 124 (54) 208 (93) 332 (73)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 123 (54) 208 (93) 331 (73)
Initially discharged but re-attended with major adverse event 1 (< 1) 0 1 (< 1)
Discharge success by initial status
Initially discharged 105 (46) 16 (7) 121 (27)
Not in hospital at 4 hours 90 (39) 16 (7) 106 (23)
In hospital at 4 hours, decision made to discharge 15 (7) 0 15 (3)
PoC, point of care; SC, standard care.
OR = 10.90 (95% CI 6.16 to 19.31), p < 0.001.
TABLE 50  Primary outcome at Frenchay
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 50 (21) 9 (4) 59 (13)
Not successfully discharged 183 (79) 222 (96) 405 (87)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 182 (78) 222 (96) 404 (87)
Initially discharged but re-attended with major adverse event 1 (< 1) 0 1 (< 1)
Discharge success by initial status
Initially discharged 51 (22) 9 (4) 60 (13)
Not in hospital at 4 hours 44 (19) 5 (2) 49 (11)
In hospital at 4 hours, decision made to discharge 7 (3) 4 (2) 11 (2)
PoC, point of care; SC, standard care.
OR = 6.74 (95% CI 3.23 to 14.07), p < 0.001.
TABLE 51  Primary outcome at Leeds
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 1 (1) 8 (5) 9 (3)
Not successfully discharged 172 (99) 163 (95) 335 (97)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 172 (99) 163 (95) 335 (97)
Initially discharged but re-attended with major adverse event 0 0 0
Discharge success by initial status
Initially discharged 1 (1) 8 (5) 9 (3)
Not in hospital at 4 hours 1 (1) 8 (5) 9 (3)
In hospital at 4 hours, decision made to discharge 0 0 0
PoC, point of care; SC, standard care.
OR = 0.12 (95% CI 0.01 to 0.96), p = 0.046.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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TABLE 52  Primary outcome at Leicester
PoC [n (%)] SC [n (%)] Total [n (%)]
Successfully discharged 50 (30) 49 (30) 99 (30)
Not successfully discharged 115 (70) 115 (70) 230 (70)
Reason for no successful discharge
In hospital 4 hours after arrival and no decision has been made to discharge 115 (70) 115 (70) 230 (70)
Initially discharged but re-attended with major adverse event 0 0 0
Discharge success by initial status
Initially discharged 50 (30) 49 (30) 99 (30)
Not in hospital at 4 hours 50 (30) 44 (27) 94 (29)
In hospital at 4 hours, decision made to discharge 0 5 (3) 5 (2)
PoC, point of care; SC, standard care.
OR = 1.02 (95% CI 0.64 to 1.63), p = 0.933.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Appendix 4  
Health economic parameter values 
used directly in model84 Appendix 4
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Appendix 5  
The RATPAC trial protocol
Project title: The RATPAC trial (HTA 06/302/19) (Randomised 
Assessment of Treatment using Panel Assay of Cardiac markers)
A randomised controlled trial (RCT) of point-of-care cardiac markers in the 
emergency department.
Planned investigation
Research objectives
We will evaluate the clinical effectiveness and cost-effectiveness of the most promising point-of-
care cardiac marker panel currently used in the emergency department (ED).
In patients presenting to the ED with suspected but not proven acute myocardial infarction 
(AMI)*, we will measure the effect of using a point-of-care cardiac marker panel upon:
1.  the proportion of patients successfully discharged home after ED assessment
2.  health utility and satisfaction with care
3.  the use of coronary care beds and cardiac treatments
4.  subsequent re-attendance at and/or re-admission to hospital
5.  major adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency 
revascularisation or hospitalisation for myocardial ischaemia)
6.  health and social care costs.
We also plan to use trial data and blood samples to evaluate:
1.  clinical prediction rules, such as the TIMI (thrombolysis in myocardial infarction) and 
GRACE (Global Registry of Acute Coronary Events) scores
2.  potential new or alternative markers, such as ischaemia-modified albumin, ultrasensitive 
cardiac troponin, B-type natriuretic peptide, myeloperoxidase and fatty acid binding protein.
*Throughout this proposal, we define AMI according to European Society of Cardiology/
American College of Cardiology (ESC/ACC) criteria for acute, evolving or recent AMI.1 
According to this definition, a troponin level above the 99th percentile of the values for a 
reference control group is considered positive, and in the context of a patient with ischaemic 
symptoms (i.e. chest pain) would satisfy the diagnosis for AMI. This definition identifies patients 
who are most likely to benefit from treatments that usually require hospital admission. Hence, it 
provides a pragmatic definition of a patient group whose suspected condition requires hospital 
admission. Setting a higher threshold for positivity would risk excluding from the definition 
patients who might benefit from hospital admission, whereas broadening the definition to 
include cases of troponin-negative acute coronary syndrome (ACS) would involve relying upon 
subjective (clinician determined) definitions of ACS and would define many patients who would 
not benefit from admission to hospital as having ACS.90 Appendix 5
Existing research
Chest pain due to suspected but not proven AMI is responsible for a substantial number of ED 
attendances and emergency hospital admissions in the UK NHS.2 Current recommendations 
suggest that these patients should receive diagnostic testing, with a troponin sample taken 
12 hours after their symptom onset,3,4 the delay being necessary because troponin sensitivity 
does not reach optimal levels until this time. This approach is inconvenient and potentially costly 
because it requires many patients to be unnecessarily admitted to hospital until the time delay 
has elapsed. Most patients with suspected AMI do not actually have AMI, so their admission will 
ultimately prove avoidable. Cost-effectiveness analysis suggests that admitting patients for cardiac 
marker testing is not a cost-effective use of health service resources.5
Evidence also suggests that these guidelines are often not followed in a busy emergency setting 
in which acute beds are limited. Collinson et al.7 showed that 7% of patients discharged after ED 
assessment for acute chest pain had elevated troponin levels at follow-up 2 days later. Goodacre 
et al.8 showed that, in the routine care arm of a randomised trial of a chest pain unit, 14% of 
patients with an elevated troponin level at 2-day follow-up had been sent home from the ED. 
Our recent national survey of EDs9 asked the lead consultant what proportion of patients with 
undifferentiated chest pain would be admitted to hospital. Estimates varied from < 20% to > 80%. 
Hence, it appears that the theoretical ideal of a 12-hour troponin is not realised in practice and, 
as a result, patients are inadvertently discharged home with AMI.
Rapid point-of-care testing using a panel of markers offers an alternative approach that may 
be more effective and cost-effective than current practice.10 A combination of markers is 
measured on arrival and a short time later (usually 90 minutes). The gradient of these markers 
(the difference between the presentation and 90-minute levels) has been shown to provide 
improved early sensitivity (95%) without unacceptably compromising specificity.11,12 A typical 
panel will use a combination of early markers, such as myoglobin or creatinine kinase (CK-
MB) (mass), and a more definitive marker, such as troponin I or T. Because the point-of-care 
tests can be used quickly in the ED, they can potentially rule out AMI during ED assessment, 
thus avoiding hospital admission and the pressure to select only high-risk patients for further 
diagnostic assessment.
Meta-analyses have estimated the diagnostic accuracy of individual cardiac markers,13,14 but there 
have been no systematic reviews of point-of-care cardiac panels.15 Our literature review found 
that studies of the diagnostic accuracy of point-of-care markers have focussed upon a panel 
using CK-MB (mass), myoglobin and troponin I measured at presentation and 90 minutes later. 
These studies have shown that the panel has high sensitivity (over 95%) and can accurately rule 
out AMI by 90 minutes after presentation.16–20 This results in earlier identification of AMI than 
laboratory testing18 and expedited decision-making with turnaround times reduced by 55%.19 
Meanwhile, comparison of patient management with the panel with previous practice showed a 
40% reduction in coronary care unit admissions.20
These studies show that the point–of-care combination of CK-MB (mass), myoglobin and 
troponin I measured at presentation and 90 minutes has appropriate diagnostic accuracy, but 
they do not reliably tell us whether the panel will alter patient care, improve outcomes or reduce 
health service costs. Early diagnostic accuracy and reduced turnaround times will only lead 
to changes in practice if clinicians act upon the additional diagnostic information. Although 
interesting, the before and after study by Ng et al.20 may be confounded by changes in coronary 
care referrals over time and, originating from the USA, where coronary care usage is much higher 
than in the UK, may not be applicable to the UK NHS. Audit data from the UK suggest that 
point-of-care cardiac testing can reduce hospital admissions, but this finding is based on before/
after audit that has yet to be published in a peer-reviewed journal.21© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Randomised trials of point-of-care testing are few in number and report conflicting results. The 
only randomised trial specifically of cardiac tests, by Collinson et al.,22 showed that point-of-care 
measurement of troponin T in patients admitted to a coronary care unit reduced overall length of 
hospital stay. By comparison, Kendall et al.23 showed that use of a variety of point-of-care tests for 
a heterogeneous group of patients in the ED produced shorter decision times, but did not reduce 
overall length of stay in the department. There are no published randomised trials evaluating the 
clinical impact of point-of-care cardiac markers in diagnostic assessment of acute chest pain.
We have searched the National Research Register and ClinicalTrials.gov for research in progress 
into point-of-care cardiac markers and have identified one relevant study.24 This is a randomised 
trial being undertaken in the USA to compare point-of-care troponin I testing with laboratory 
testing in acute coronary syndrome to determine whether bedside use leads to shorter decision 
times in emergency care. It will therefore provide useful data for North American decision-
makers to determine whether replacing laboratory with point-of-care troponin testing leads to 
more efficient patient processing. However, it will not determine whether a rapid rule-out point-
of-care strategy is more effective or cost-effective than routine care, particularly in the UK.
Research methods
We will undertake a pragmatic randomised controlled trial and economic evaluation of a point-
of-care cardiac marker panel in the management of patients with suspected, but not proven, AMI 
in six EDs in the UK.
Emergency department staff will identify eligible patients, provide trial information and obtain 
written consent. Participants will then be randomly allocated to receive either (1) diagnostic 
assessment using the point-of-care biochemical marker panel or (2) conventional diagnostic 
assessment without the panel.
The Sheffield Clinical Trials Research Unit (CTRU) will generate a simple randomisation 
sequence, stratified by centre, which will not be revealed to any person involved in patient 
recruitment. ED staff will telephone the CTRU randomisation service when they recruit a 
participant and will provide full participant details to the CTRU. The CTRU will reveal the 
participant’s allocated treatment group to the ED only after the participant’s details have been 
recorded, written consent has been confirmed and the participant irrevocably entered into 
the trial.
This is a pragmatic trial that is intended to determine whether point-of-care testing should be 
standard practice for patients presenting to the ED with suspected AMI. It is designed to compare 
two pragmatic alternatives (management with and without point-of-care testing) under routine 
conditions to determine whether use of the test changes costs or outcomes. This pragmatic design 
has the following implications:
1.  After randomisation we will not attempt to blind clinical staff, patients or carers to the 
allocated treatment group.
2.  Although the point-of-care test will be provided with a recommended protocol for use, 
management decisions will ultimately be at the discretion of the clinical staff.
3.  All other diagnostic tests and the use of laboratory blood tests in the control group will be at 
the discretion of the clinical staff.
4.  Blood samples will only be taken for the purposes of clinical management. We will not take 
additional blood samples to evaluate theoretical management strategies or to evaluate the 
accuracy of diagnostic assessments. We will not take additional samples to evaluate new 
markers (as set out in the secondary objectives) but will use residual blood from point-
of-care tests.92 Appendix 5
Justification for choice of research methods
During the development of this proposal, we considered two other alternative methods of 
evaluation:
1.  systematic review and modelling
2.  cluster randomised trial.
We propose a pragmatic trial, as opposed to systematic review and modelling, because key pieces 
of information that are central to the estimation of cost-effectiveness are not yet available. First, 
as outlined above, while there are abundant data available to estimate the diagnostic accuracy of 
the constituent point-of-care panel tests, only limited data are available to estimate the diagnostic 
performance of the overall panel, with no studies based in the UK. This is potentially important 
as differences in patient characteristics and presentation patterns are likely to have an impact on 
sensitivity and specificity.
Second, even if these data were used, the behavioural consequences of the test results are 
unknown: which patients will and will not be admitted, how long will they be admitted for? 
Likewise, as identified by our previous work in this area,5,8 it is very difficult to determine how 
patients receiving point-of-care testing would have been managed if the point-of-care test were 
not available. Assuming that all patients would have been admitted to hospital for laboratory 
troponin testing at 12 hours after symptom onset is inappropriate and would overestimate the 
comparative cost-effectiveness of point-of-care testing.
Finally, if we were to model admission rates as a function of sensitivity/specificity using our 
previous work, and then interpolate the sensitivity/specificity estimates for point-of-care panels, 
we would have to make cavalier assumptions about the form that the relationship takes due to the 
paucity of data points.
Taken together, we firmly believe that there would currently be excessive uncertainty around 
key parameters in any cost-effectiveness model. However, based on the results of this study and 
others that may be published in the meantime, we feel that sufficient evidence will be available 
for different panels to be evaluated using the model developed as part of this proposal. The need 
for any further research will also be evaluated using a value of information analysis based around 
this model.25
We propose to randomise individual patients, rather than using cluster randomised methods, 
because the advantages of cluster randomised methods, of reducing the risk of contamination or 
non-compliance in the control group, are outweighed by the disadvantages of selection bias due 
to loss of allocation concealment and loss of statistical power.
Cluster methods based upon randomising periods of time, such as days of the week, would not 
significantly reduce the risks of contamination, so we would have to randomise large clusters, 
such as members of staff or whole hospitals. This would involve substantial loss of statistical 
power. More importantly, there would be a substantial risk of selection bias because recruiting 
staff would be aware of whether patients would be allocated to point-of-care testing or not and 
might apply exclusion criteria in a differential manner, depending upon whether they wanted to 
use point-of-care testing or not. This could result in patients being recruited to the point-of-care 
arm of the trial if they were considered appropriate for point-of-care testing, and recruited to 
the control arm if they were considered appropriate for routine care. This would represent a 
substantial flaw.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Individual patient randomisation allows us to achieve allocation concealment and avoid the 
risk of selection bias. Although it carries the risk of contamination and non-compliance in the 
control group we can explore for evidence of contamination by examining changes in control 
group practice and admission rates over time. We will minimise the risk of non-compliance in 
the control group by limiting the availability of point-of-care testing to consecutively numbered 
test ‘strips’ that are used only in recruited intervention group patients, and are recorded and 
accounted for at the end of the trial.
Planned interventions
Participants will be randomised to receive either:
1.  diagnostic assessment using the point-of-care biochemical marker panel
or
2.  conventional diagnostic assessment without the panel.
The only difference between the two arms of the trial will be that patients in the intervention arm 
will receive testing with the point-of-care panel. The use of all other tests and treatments, and 
decision-making in the ED, will be at the discretion of the attending clinician.
The point-of-care cardiac marker panel will comprise CK-MB (mass), myoglobin and troponin 
I, measured at presentation and 90 minutes later, using the Stratus CS point-of-care analyser. 
As outlined above, this combination has been widely evaluated in practice.16–20 Of the systems 
currently available, or soon to be available, the latest version of the Dade Behring Stratus CS 
Analyser has the most data as an instrument suitable both for the emergency laboratory and for 
use as a point-of-care testing (POCT) instrument.26
Clinical staff will be trained to use the test and give guidance in interpretation of the results. We 
will provide a recommended protocol that will advise a first panel test immediately after initial 
ED assessment and a second panel test 90 minutes later. Other than obtaining consent, collecting 
data, and random allocation to use of the point-of-care test, the only change to routine practice 
will be that we will ask clinical staff to take an additional quantity of blood for storage (without 
repeating venepuncture) each time a blood sample is required.
The additional blood remaining after POCT has been performed will be transported to the 
hospital laboratory, where it will be centrifuged and refrigerated. Batches of samples will be 
transported quarterly to St George’s Hospital for analysis to address the secondary objectives of 
the study.
Planned inclusion/exclusion criteria
We will recruit people presenting to the ED with chest pain due to suspected but not proven 
AMI in whom a negative point-of-care marker test could potentially rule out AMI and allow 
discharge home.
We will exclude the following
1.  Patients with diagnostic ECG changes for AMI or high-risk acute coronary syndrome 
(> 1 mm ST deviation or > 3 mm inverted T waves). These patients are at high risk of adverse 
outcome and require inpatient care, even if marker tests are negative.
2.  Patients with known coronary heart disease (CHD) presenting with prolonged (> 1 hour) 
or recurrent episodes of typical cardiac-type pain. These patients have unstable angina and 
require inpatient care for symptom control even if marker tests are negative.94 Appendix 5
3.  Patients with proven or suspected serious non-coronary pathology (e.g. pulmonary embolus) 
that requires inpatient care, even if AMI is ruled out.
4.  Patients with comorbidity or social problems that require hospital admission even if AMI 
can be ruled out.
5.  Patients with an obvious non-cardiac cause (e.g. pneumothorax or muscular pain), in whom 
AMI can be excluded as a possible cause without resorting to further diagnostic testing.
6.  Patients presenting more than 12 hours after their most significant episode of pain, for 
whom a single troponin measurement would clearly be more appropriate than point-of-care 
panel testing.
7.  Previous participants in the RATPAC trial.
8.  Patients who are unable to understand the trial information due to cognitive impairment.
9.  Non-English speaking patients for whom translation facilities are not available.
The research nurse at each hospital will regularly check ED attendance lists to identify patients 
attending with chest pain and record basic demographic details and reason for exclusion, thus 
allowing completion of a CONSORT flow chart.
Proposed outcome measures
The primary outcome will be the proportion of patients successfully discharged home after ED 
assessment, defined as discharge with no adverse event (as defined below) during the following 
3 months.
Secondary outcomes will include:
1.  Health utility measured using the European Quality of Life-5 Dimensions (EQ-5D) self-
complete questionnaire at 1 and 3 months after attendance.
2.  Satisfaction with care measured at 1 month after attendance using a modified Group Health 
Association of America questionnaire that has been used successfully in previous studies of 
diagnostic strategies for acute chest pain.
3.  The proportion of patients managed on the coronary care unit, receiving cardiac medications 
(such as heparin, clopidogrel or glycoprotein IIb/IIIa inhibitors) or receiving cardiac 
interventions (such as angiography, percutaneous intervention or bypass grafting).
4.  Re-attendance at and/or re-admission to hospital over the following 3 months.
5.  Adverse events (death, non-fatal AMI, life-threatening arrhthymia, emergency 
revascularisation or hospitalisation for myocardial ischaemia).
6.  The proportion of admitted patients ultimately diagnosed as having AMI by ESC/
ACC criteria.1
We have selected successful discharge home as the primary outcome because the main purpose 
of point-of-care cardiac marker testing in this patient group is to facilitate discharge home. This 
outcome is beneficial for patients, who avoid the inconvenience and risks of hospital admission, 
and is beneficial for the health service, which avoids unnecessary admissions and pressure upon 
acute and emergency services. Patients who suffer an adverse event after discharge will not be 
classified as a successful discharge home because it is possible that they would have benefited 
from hospital admission. We will also record the proportion of admitted patients who are 
ultimately diagnosed as having AMI to provide a measure of the appropriateness of admissions.
Assessment of outcomes
Recruiting staff will record baseline data, the results of initial assessment (including any 
biochemical cardiac tests), data required for TIMI27 and GRACE28 scoring and admission/
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record management decisions at initial attendance and admission, extract resource use data and 
identify subsequent attendances/admissions and adverse events up to 3 months.
Research nurses will check patient status (dead or alive) at 1 and 3 months, using hospital 
information systems. Deceased patients will be assumed to have a score of zero on EQ-5D and 
will be excluded from other patient-based assessments. Participants who are not recorded as 
dead will be mailed a questionnaire at 1 and 3 months from the University of Sheffield to identify 
adverse events and hospital attendances, health and social care resource use, and to measure 
EQ-5D and satisfaction with care (satisfaction at 1 month only). Our previous study suggests a 
70–80% response rate to this questionnaire.8 We will therefore contact the general practitioner of 
all participants who do not respond at 3 months after attendance to identify any serious adverse 
events or deaths that have not been recorded by hospital information systems or case notes. 
Classification of cases of AMI and adverse events will be done by blind independent review of the 
relevant data.
Proposed sample size (N = 3130)
We anticipate that 50% of subjects will be successfully discharged in the group managed without 
the marker panel.8 With 1565 evaluable subjects in each arm of the trial we will have 80% 
power to detect a 5% improvement (to 55% of patients successfully discharged) at the two-sided 
significance level of 5%. The same sample size will provide 80% power to detect a reduction 
from 4% to 2% in major cardiac events (death, non-fatal AMI, emergency revascularisation or 
hospitalisation for myocardial ischaemia), again at the two-sided 5% level of significance.
Based on previous studies by members of our research team, we estimate that we will require 
six hospitals to recruit for 12 months each to achieve the sample size of 3130, assuming that 
we recruit 70% of those eligible.8,29–31 We have undertaken a number of studies of this specific 
patient group and have shown that recruitment of 550 suitable patients per year is attainable at a 
typical hospital.
Previous studies have also shown that we can anticipate a response rate of 70–80% for postal 
questionnaires,8,29 thus providing an effective sample size of at least 1000 in each of the two 
groups to evaluate health utility, satisfaction with care and health service resource use.
Statistical analysis
The primary outcome will be analysed through logistic regression, fitting concurrently with 
intervention group the effect of centre and appropriate baseline measures (including age, gender 
and past history of CHD). The results will be presented as adjusted odds ratios along with their 
corresponding 95% CIs. A similar analysis will be undertaken on major cardiac events. The 
primary analysis will be undertaken on an intention-to-treat basis. A secondary analysis will 
exclude those who were not managed according to their allocated strategy.
We will undertake a descriptive assessment to explore whether use of biochemical cardiac 
markers or admission rates change over time in either the intervention or control group, either as 
a result of staff ‘learning curves’ in the intervention group or as a result of contamination of the 
control group.
Analysis of secondary objectives
The secondary objectives of evaluating clinical prediction rules, such as the GRACE and TIMI 
scores, will be addressed by analysing the proportion of participants in each risk stratum of the 
score who suffer an adverse event over 30-day follow-up. Receiver-operator characteristic (ROC) 
curves will be constructed to estimate the discriminant power of the scores for adverse events.96 Appendix 5
Blood stored at St George’s Hospital will be used to analyse potential alternative cardiac markers 
and any new cardiac markers that are developed. We will analyse the association between 
marker levels and adverse events within 30 days. The data will then be split into derivation and 
validation data sets. ROC curves will be constructed using the derivation data set to estimate 
the discriminant power of the markers and to identify, alongside economic modelling, optimal 
thresholds for decision-making. The validation set will then be used to estimate sensitivity and 
specificity at the optimal threshold.
Economic evaluation
An economic evaluation will be undertaken alongside the trial using recommended practice.32 To 
supplement this analysis, a cost-effectiveness model will be developed to duplicate the trial results 
(as a way of validation), extrapolate the results to longer follow-up periods, and incorporate a 
value of information analysis. The NHS perspective undertaken and other methods will be in 
line with NICE Technology Appraisal Guidelines,33 although data on production losses will be 
collected for a supplementary analysis.
Resource-use data will be collected for all patients covering the length of time in the ED, the 
use of diagnostic tests, admissions, re-admissions, outpatient reviews, cardiac procedures, and 
time off work. Cost and outcome data will be collected using patient notes and self-completed 
questionnaires as described previously. A small microcosting study will also be carried out at 
each site for a fortnight (to include around 30 patients), gathering data on staff times relating 
to the care of patients. ED cost per minute will be based on a study previously undertaken by 
the investigators,8 and amended using the microcosting data from this study. Panel costs will 
be based on purchase price, and the remaining costs will be valued using national unit costs.34,35 
Total NHS cost up to 3 months after initial attendance will then be calculated. Quality-adjusted 
life-years (QALYs) will be calculated by the trapezium rule using the EQ-5D tariff values at all 
follow-up points.
Economic analysis
Both cost and QALY analysis will compare bootstrap estimates of the mean cost per patient 
of the two groups. Cost-effectiveness analysis will estimate the incremental cost per QALY of 
using point-of-care cardiac marker testing compared with management without point-of-care 
testing. Results will be plotted on the cost-effectiveness plane and then transformed into cost-
effectiveness acceptability curves with their associated frontier.36 A sensitivity analysis will be 
undertaken that will include production losses as reported by the patient.
We anticipate that some of the resource use and QALY data will be incomplete (missing). Thus, 
in order to maximise the information that is collected from the trial we will impute missing 
values using multiple imputation.37 The idea of multiple imputation draws from the fact that 
missing values from incomplete data are unknown and the technique of multiple imputation 
imputes more than one likely value for the missing data; hence, providing a representation of 
uncertainty.38 Thus an additional set of results will be produced including the imputed cost and 
QALY data.
Decision-analytic model
We will also construct a decision-analytic model to describe the care observed in the trial, and 
likely care pathways subsequent to it. This will allow us to systematically investigate the impact 
of subsequent costs, quality of life and survival. These values will initially be based on population 
norms, but replaced with literature review estimates where appropriate. The decision-analytic 
model will be probabilistic, but with conventional sensitivity analysis used to assess the impact of 
structural uncertainties.39© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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One important aspect of the model will be to investigate the relationship between sensitivity/
specificity and admission rates. This will be modelled using all available studies of diagnostic 
testing in EDs. This part of the model is important, as it will help us to estimate cost-effectiveness 
of different panels in the future.
The decision-analytic model will be used to produce a value of information analysis. In particular, 
the analysis will generate partial expected value of perfect information estimates for each 
parameter in order to help prioritise future research.
Ethical arrangements
All participants will be asked to provide written, informed consent. This will include consent to 
allow research staff to examine their hospital records and contact their GP. Although participants 
will be recruited in an emergency setting and there will only be a limited amount of time 
available for considering trial information, the nature of the selected group (in particular the 
exclusion of people clearly requiring hospital treatment) ensures that eligible patients should not 
be incapacitated by their medical condition. We do not therefore plan to recruit incapacitated 
patients, and do not need to make provision for recruitment by personal or professional 
legal representatives.
Risks to participants are small, but include the following:
1.  Inappropriate recruitment of high-risk patients or those with other serious non-cardiac 
pathology leading to risk of inappropriate discharge home. We will minimise this risk using 
regular review by the research nurses to identify inappropriately recruited participants. 
Inappropriate discharge of high-risk patients is, of course, a risk outside the confines of this 
trial. Indeed, a potential benefit to participants is that inclusion in a carefully audited trial 
should reduce their risk of mismanagement.
2.  Failure of point-of-care testing to identify AMI leading to inappropriate discharge home. We 
have minimised this risk by choosing a widely used point-of-care test that has been shown 
to have high sensitivity for AMI in previous studies.16–20 Furthermore, our own previous 
studies7,8 show that routine care (i.e. without point-of-care testing) is associated with a 
significant risk of inappropriate discharge home that appears to be reduced when rapid 
diagnostic testing protocols are available.
3.  Distress to participants or their relatives if the postal questionnaire is sent to someone who 
is seriously ill or recently deceased. We will minimise this risk by ensuring that the research 
nurses check patient status on hospital information systems at 1 and 3 months, before 
questionnaires are mailed.
Submission to a Multicentre Research Ethics Committee is currently under way. We will complete 
Local Research Ethics Committee reviews during the first 6 months of the timetable.
Research governance
This trial will be conducted in accordance with MRC Guidelines for GCP in Clinical Trials. It does 
not involve a medicinal product and is not covered by the Medicine for Human Use (Clinical 
Trials) Regulations 2004. The University of Sheffield will act as the sponsor for the trial.
Three committees will be established to govern the conduct of this study:
  ■ Trial Steering Committee
  ■ Independent Data Monitoring and Ethics Committee (DMEC)
  ■ Trial Management Group.98 Appendix 5
The Trial Steering Committee will consist of the Principal Investigator, one of the co-applicants, 
an independent chair, two independent members and a consumer representative (Enid Hirst). 
We will also invite a representative of the HTA board to join the committee. The DMEC will 
consist of a minimum of an independent statistician, emergency physician and cardiologist, who 
will be asked to review trial data at regular intervals and implement stopping rules in accordance 
with MRC guidance. The Trial Management Group will consist of the Principal Investigator, 
co-applicants, project manager, statistician, health economists and research nurses.
Data management
Trial data will be entered into a validated database system, built to a specification agreed between 
Sheffield CTRU and the Principal Investigator. The system will be accessible remotely via a web 
browser, with the data stored securely on a central server. Access will be controlled by the use of 
assigned logins and encrypted passwords. The system will have a full electronic audit trail and 
will be regularly backed up. Quality control procedures will be applied to validate the trial data. 
Error reports will be generated where data clarification is required. Output for analysis will be 
generated in a format and at intervals to be agreed between Sheffield CTRU and the Principal 
Investigator. All activities will be performed in accordance with Sheffield CTRU Standard 
Operating Procedures.
Project timetable and milestones
The project will start on 1 April 2007. Months 1–6 will involve staff recruitment and local ethics 
and research governance; months 7–18 will involve patient recruitment; and months 19–24 will 
involve completion of follow-up, data analysis, writing up and dissemination. The project will be 
completed by 31 March 2009. The GANTT below outlines the key milestones and shows when 
project staff will be employed.
Month of project
1–3 4–6 7–9 10–12 13–15 16–18 19–21 22–24
Trial manager XXX XXX XXX XXX XXX XXX XXX XXX
Trial researcher XXX XXX XXX XXX
Clerical assistant XXX XXX XXX XXX XXX XXX XXX XXX
Research nurses × 6 XX XXX XXX XXX XXX XXX X
Staff recruiting, ethics, R&D XXX XXX
Patient recruitment XXX XXX XXX XXX
Follow-up XX XXX XXX XXX XXX
Analysis XXX
Writing up XXX
We will submit 6-monthly progress reports corresponding with the following milestones:
1.  completion of ethics and governance procedures and commencement of recruitment in all 
six sites
2.  mid-point of recruitment, with a target of 1200 participants recruited (allowing for initial lag 
phase in recruitment)
3.  end of recruitment, with 3130 participants recruited
4.  completion of analysis and final report.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by 
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Expertise
The trial will be coordinated by a trial manager in the Sheffield CTRU, working with full 
statistical, clinical trials and health economic support. The applicants are a multidisciplinary 
team with expertise in health service research, emergency medicine, cardiology, chemical 
pathology, epidemiology, health economics and statistics. The researchers are leading experts in 
the management of acute chest pain and have undertaken previous landmark investigations in 
this field, including the ESCAPE trial of chest pain units8,40 (SG, SC, SD), randomised evaluation 
of point-of-care cardiac markers in coronary care22 (PC), evaluation of ischaemia-modified 
albumin in emergency care31,41 (JB, PC, SG), and evaluation of cardiac biomarkers (PC). We 
have also collaborated to successfully undertake a previous HTA-funded multicentre trial in 
emergency care, the 3CPO Trial42 (AG, SG, DN, JB). The co-applicants from Leeds (AH, JB, TH) 
have recently undertaken studies of biomarkers in patients with acute chest pain and studies in 
AMI.43,44
Service users
Enid Hirst, a health service user representative, has provided valuable input into previous projects 
undertaken by our team. She has agreed to provide user involvement in the development of the 
proposal and be user representative on the Trial Steering Group. She has also created a CHD user 
group consisting of five people with CHD and their main carer/relative. This group has provided 
guidance to previous projects, notably our evaluation of the National Infarct Angioplasty Pilots. 
We are using this group to develop our proposal: specifically to identify relevant outcome 
measures, and ensure appropriate procedures are used for consent and follow-up.
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